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Abstract  
The ability of mitochondria to take up Ca2+ plays a fundamental role in the 
regulation of several biological processes [1]. In the last five years, the molecular 
and functional characterization of the MCU machinery pictures this Ca2+ channel 
as one of the most sophisticated ion channels described so far [2]. These 
groundbreaking discoveries have opened a new era for the study of mitochondrial 
Ca2+ in cell physiology and will allow to deepen the knowledge on the tissues-
specific properties of MCU [3] that are still poorly understood.  
In this regard, we identified an alternative splice isoform (hereafter named 
MICU1.1) of the positive MCU modulator MICU1, characterized by the addition 
of a micro-exon coding for 4 amino acids (EFWQ), conserved in vertebrates. 
Interestingly, while MICU1 is ubiquitously expressed, MICU1.1 shows a peculiar 
tissues distribution, being highly expressed in tissues that display the greatest level 
of mitochondrial Ca2+ uptake, skeletal muscle and lower levels are found in brain.  
Immunoprecipitation experiments performed in HeLa cells assessed that 
MICU1.1 efficiently interacts with MCU and MICU2. Furthermore, MICU1.1 is 
able to form homo- and heterodimers with MICU2, as well as MICU1. Nonetheless, 
the overexpression of MICU1.1 in HeLa cells causes a major increase of 
mitochondrial Ca2+ uptake upon histamine stimulation compared to conventional 
MICU1, without affecting neither cytosolic Ca2+ values nor the mitochondrial 
membrane potential. Strikingly, MICU2 overexpression in cells expressing 
MICU1.1 is unable to block the increase of mitochondrial Ca2+ uptake induced by 
MICU1.1. On the contrary, the co-expression of MICU1.1 together with MICU2 
further increases mitochondrial Ca2+ uptake speed compared to cells overexpressing 
MICU1.1 alone. On the other hand, MICU1.1, when bound to MICU2, is able to 
act as gatekeeper of the channel at resting Ca2+ levels as well as MICU1-MICU2 
heterodimer. Importantly, we found that MICU1.1-MICU2 overexpression induces 
the shift of the threshold of MCU opening towards lower Ca2+ concentrations. 
Consistently with previous results on MICU1, MICU1.1 function is 
dependent on its ability to bind Ca2+. Indeed, a MICU1.1 mutant, insensitive to 
Ca2+, displays a dominant-negative effect on mitochondrial Ca2+ uptake. On the 
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contrary, MICU1.1 is less affected by the dominant-negative effect of mutated 
MICU2, insensitive to Ca2+ binding. 
We also analysed the contribution of the extra-exon to the particular 
behaviour of MICU1.1. We observed that single mutations or deletions of these 
residues do not influence the effect of MICU1.1 on mitochondrial Ca2+ uptake. On 
the contrary, the substitution of all the four amino acids of the extra-exon with four 
alanine residues is sufficient to recapitulate MICU1 behaviour. 
In conclusion, we characterized a transcript variant of MICU1, which is 
specifically expressed in excitable tissues, prevalently in skeletal muscle, and that 
shows a higher ability to activate MCU compared to conventional MICU1. 
Interestingly, MICU1.1 exerts a peculiar function when bound to MICU2. Overall, 
our data demonstrate a skeletal muscle-specific mitochondrial Ca2+ uptake 
machinery with a presumably unique function. Thus, in this tissue, mitochondrial 
Ca2+ can exert new, unexplored roles. Future experiments have to be performed to 
clarify its physiological and pathological relevance. 
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Riassunto 
La capacità dei mitocondri di accumulare Ca2+ riveste un ruolo cruciale nella 
regolazione di numerosi processi fisiologici [1]. Negli ultimi cinque anni, la 
caratterizzazione dell’identità molecolare e funzionale del complesso dell’uniporto 
mitocondriale per il calcio (MCU) ha delineato questo canale come uno dei canali 
più complessi finora descritti [2]. Questa scoperta rivoluzionaria ha inaugurato una 
nuova era per lo studio del ruolo del Ca2+ mitocondriale nella fisiologia cellulare e 
ha permesso di approfondire i meccanismi di regolazione tessuto-specifici di MCU 
[3], ad oggi ancora poco chiari. 
A questo proposito, abbiamo identificato una variante di splicing del modulatore 
positivo di MCU, MICU1. Questa variante di splicing, che abbiamo chiamato 
MICU1.1, è il risultato di un evento di splicing alternativo che determina l’aggiunta 
di un micro-esone, conservato in tutti i vertebrati, codificante per quattro 
aminoacidi (EFWQ). Mentre MICU1 è espresso, seppur a diversi livelli, in tutti i 
tessuti, MICU1.1 presenta una distribuzione peculiare. Infatti, MICU1.1 è molto 
espresso nei tessuti che sono noti avere un elevato ingresso di Ca2+ nei mitocondri, 
ovvero il muscolo scheletrico e il tessuto nervoso, mentre è assente in tutti gli altri. 
Esperimenti di immunoprecipitazione effettuati in cellule HeLa hanno dimostrato 
che MICU1.1 interagisce con MCU e MICU2. Inoltre, MICU1.1 è in grado di 
formare omodimeri e eterodimeri con MICU2, come già osservato per MICU1. 
Nonostante ciò, la sovraespressione di MICU1.1 in cellule HeLa causa un aumento 
dell’entrata di Ca2+ mitocondriale maggiore rispetto a MICU1, senza influenzare né 
i valori di Ca2+ citosolici né il potenziale di membrana mitocondriale. 
Sorprendentemente, la co-espressione di MICU2 in cellule sovraesprimenti 
MICU1.1 non limita l’incremento di ingresso di Ca2+ nei mitocondri indotto dalla 
sovraespressione di MICU1.1. Al contrario, la co-espressione di MICU1.1 e 
MICU2 causa un aumento della velocità di entrata di Ca2+ nei mitocondri, che 
risulta essere maggiore rispetto a quella osservata in seguito alla sola 
sovraespressione di MICU1.1. Tuttavia, in condizioni basali, MICU1.1, quando 
forma eterodimeri con MICU2, causa la chiusura del canale allo stesso modo 
dell’eterodimero MICU1-MICU2. Ciononostante, abbiamo osservato che la 
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sovraespressione di MICU1.1 con MICU2 induce un abbassamento della soglia di 
attivazione di MCU verso concentrazioni di Ca2+ più basse. 
Come già dimostrato in precedenti studi su MICU1, anche la funzione di MICU1.1 
dipende dalla capacità di questa proteina di legare Ca2+. Infatti, un mutante di 
MICU1.1 insensibile ai livelli di Ca2+, agisce da dominante negativo sull’entrata di 
Ca2+ nel mitocondrio. 
Abbiamo anche dimostrato che il comportamento peculiare di MICU1.1 dipende 
dai residui che compongono l’esone addizionale. I risultati ottenuti dimostrano che 
la singola mutazione di uno di questi residui (in particolare la sostituzione con 
alanina o la delezione) non influenza l’effetto di MICU1.1 sull’ingresso di Ca2+ nel 
mitocondrio. Tuttavia, la sostituzione di tutti e quattro gli aminoacidi con 
l’aminoacido alanina è sufficiente a ristabilire il comportamento di MICU1. 
In conclusione, durante il mio periodo di dottorato ho caratterizzato una variante di 
splicing di MICU1, che è selettivamente espressa in tessuti eccitabili e che attiva 
MCU più efficientemente di MICU1. Sorprendentemente, ho osservato che 
MICU1.1 esercita una funzione peculiare quando legato a MICU2. 
Complessivamente, i nostri dati dimostrano che nei tessuti eccitabili esiste un 
complesso molecolare per l’ingresso di Ca2+ nei mitocondri con una funzione unica. 
Quindi, in questi tessuti, l’ingresso di Ca2+ nei mitocondri riveste funzioni nuove e 
ancora inesplorate. Ulteriori studi saranno necessari per chiarire il ruolo di 
MICU1.1 in diverse condizioni fisiologiche e patologiche. 
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Introduction 
Ca2+ Signalling 
Cell signalling is an intricate system of communication that directs basic 
cellular activities and coordinates cell functions. The ability of cells to sense and 
correctly respond to their microenvironment is the basis of development, tissue 
repair, and immunity, as well as normal tissue homeostasis. For this purpose, during 
evolution a plethora of mechanisms has evolved in order to fulfill the huge request 
of communication. Many of these mechanisms converge on a relative small number 
of messenger molecules, which are responsible to trigger an appropriate 
intracellular response. These molecules, called second messengers, share some 
particular properties: they are rapidly released in response to stimuli and they are 
also rapidly neutralized, allowing time and space limitation of the signal. 
Importantly, second messengers enable the amplification of the starting stimulus 
[4]. 
The divalent ion calcium (Ca2+) is one of the most important second 
messengers, as once it enters the cytosol it exerts allosteric regulatory effects on 
many enzymes and proteins, impacting nearly every aspect of cellular life. This is 
corroborated by the amount of energy that cells invest to affect changes in Ca2+ 
concentration ([Ca2+]). Indeed, while complex molecules can be chemically altered, 
the only mechanisms that exert control over Ca2+ are chelation, subcellular 
compartmentalization and cell extrusion. For this purpose, hundreds of cellular 
proteins have been adapted to bind Ca2+, in some cases simply to buffer or lower 
Ca2+ levels, and in others to trigger cellular processes [5]. Hundreds of proteins 
chelator of Ca2+ share a common Ca2+-binding motif, the EF-hand domain [6]. 
The consequence of this precise control of [Ca2+] is a very steep gradient of 
Ca2+ across the plasma membrane of cells: cytosolic Ca2+ ([Ca2+]cyt) is maintained 
at 10-100 nM, while the extracellular milieu generally presents a [Ca2+] of over 1 
mM [7]. 
Ca2+, which acts as second messenger in the cell, is retrieved from two main 
sources: the extracellular milieu and the internal stores. The most important Ca2+ 
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store in the cell is the endoplasmic reticulum (ER) [7], but some recent studies 
demonstrated that also other organelles, such as the Golgi apparatus, the endosomes 
and lysosomes are able to contribute to Ca2+ signalling [8–10].  
One of the most common mechanism of intracellular Ca2+ release from ER 
is represented by inositol 1,4,5-trisphosphate (IP3), a second messenger that is 
released as a consequence of a plethora of external stimuli [11]. IP3 induces the 
release of Ca2+ from the ER, acting on its receptor, IP3 Receptor (IP3R). This 
IP3/Ca2+ signalling system is a key regulator of many cellular control 
mechanisms[11]. Once Ca2+ has carried out its signalling functions, it is rapidly 
removed from the cytoplasm by extrusion or by compartmentalization thanks to 
various pumps and exchangers [7], allowing intracellular [Ca2+] to return to its 
resting conditions. The rapid release and re-uptake of Ca2+ result in waves of Ca2+ 
that propagate within the cell, whose mechanisms and actions must be defined for 
each cell and tissue type.  
Mitochondria 
The general framework  
Mitochondria represent unique organelles within the complex 
endomembrane systems that characterize any eukaryotic cell. Beyond the pivotal 
task of these organelles in regulating the production of ATP, a complex 
mitochondrial biology has emerged in the last decades. Indeed, mitochondria 
participate in many other aspects of cell homeostasis such as aminoacid synthesis, 
lipid metabolism, Ca2+ signalling, reactive oxygen species (ROS) production and 
cell death regulation [12,13]. Accordingly, it is now widely accepted that 
mitochondrial dysfunction is associated with several physiopathological conditions, 
including neurodegenerative diseases (Alzheimer’s, Hungtinton’s, Parkinson’s 
diseases), motoneuron disorders (amyotrophic lateral sclerosis), ischemia-
reperfusion injury, diabetes, ageing and cancer [13–17]. 
The understanding of the pivotal role of mitochondria as integration point 
of different cellular signals, and how mitochondria translate these stimuli in 
biological responses represent a new challenge in biomedical research. 
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Two structurally and functionally different membranes delimitate 
mitochondrial matrix: the outer membrane (OMM), permeable to ions and 
metabolites up to 5000 Daltons (Da), and the highly selective inner membrane 
(IMM), characterized by invaginations, called cristae, which enclose the 
mitochondria matrix. These two membranes delimitate the intermembrane space 
(IMS). The cristae define internal compartments formed by profound invaginations 
originating from narrow tubular structures, called cristae junctions [18] that limit 
the diffusion of molecules from the intra-cristae space towards the IMS. This space 
delimitates a micro-environment where the mitochondrial Electron Transport Chain 
(ETC) complexes are hosted and other proteins are protected from random diffusion 
[18].  
The most important task of mitochondria is ATP production by oxidative 
phosphorylation. In 60s, Peter Mitchell shed light on the process by which electron 
transfer is coupled to ATP synthesis, proposing for the first time an indirect 
mechanism, the chemiosmotic theory [19,20]. Indeed, he suggested that the flow of 
electrons through the respiratory ETC complexes drives protons across the IMM of 
mitochondria, creating an electrochemical proton gradient across the membrane 
[21,22]. The synthesis of ATP is driven by a reverse flow of protons down the 
gradient through the F1/Fo ATPase. This big protein complex uses the energy 
relieved by proton flow down the electrochemical gradient to carry out ATP 
production. This electrochemical gradient across the IMM is reflected in a huge 
membrane potential difference (ΔΨm) of -180 mV (negative inside) [21,22]. 
Mitochondrial Ca2+ signalling  
An historical perspective 
About sixty years ago, even before of chemiosmotic theory, pioneering 
studies demonstrated that energized mitochondria can rapidly and efficiently 
accumulate Ca2+ [23–25]. In the following years, the basic properties of the 
mitochondrial Ca2+ transport were clarified: the accumulation of Ca2+ into the 
mitochondrial matrix through the ion-impermeable IMM occurs via an electrogenic 
pathway that involves the mitochondrial Ca2+ uniporter (MCU). This channel 
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allows the rapid accumulation of Ca2+ in the matrix, thanks to the steep 
electrochemical gradient that acts as an enormous driving force attracting the 
divalent ion. Ca2+ accumulation by MCU does not proceed until electrochemical 
equilibrium due to the activity of two main efflux pathways, the Na+/Ca2+ (mNCX) 
and H+/Ca2+ (mHCX) exchangers [26]. 
In the 80s, the accurate [Ca2+]cyt measurement obtained with fluorescent 
indicators demonstrated that the low affinity of MCU would not allow substantial 
Ca2+ uptake into the organelle with the [Ca2+]cyt revealed by measurements in basal 
and stimulated conditions. Thus, the study of the role of mitochondria in Ca2+ 
homeostasis became marginal. 
The situation completely reversed with the development of genetically 
encoded Ca2+ probe specifically targeted to mitochondria [27]. Indeed, these probes 
allowed to follow the mitochondrial Ca2+ concentration ([Ca2+]mt) changes during 
cell stimulation upon agonist-induced [Ca2+]cyt increases. It was observed that the 
speed and the amplitude of Ca2+ accumulation into mitochondria greatly exceed the 
values that were previously predicted on the basis of MCU properties in isolated 
mitochondria. In addition, upon agonist stimulation, [Ca2+]mt reaches much higher 
values than the levels in the cytosol [27]. 
The microdomain concept  
The discrepancy between this prompt response and the low affinity of the 
Ca2+ transporter was reconciled by the discovery that mitochondria are strategically 
located in close proximity of Ca2+ channels responsible of cytosolic Ca2+ waves 
[28]. Therefore, mitochondria sense microdomains of high [Ca2+]cyt that meet the 
low affinity of the MCU. In detail, it has been observed that mitochondria form 
quasi-synaptic junctions with ER membranes thus allowing the close proximity of 
ER-resident Ca2+ channels to mitochondria [28–32]. Thanks to a GFP-based Ca2+ 
probe localized on the cytosolic surface of the OMM, it was demonstrated that, 
upon Ca2+ mobilization, the [Ca2+] in small regions of the mitochondrial surface 
reaches levels 5- to 10-fold higher than in the bulk cytosol [33]. This high [Ca2+]cyt 
microdomains are sufficient to ensure a rapid Ca2+ entry through MCU, but on the 
other hand, thanks to the rapid dissipation of the Ca2+ transient, it acts as a safety 
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lock that prevents mitochondrial Ca2+ overload and vicious cycling of Ca2+ through 
mitochondrial membranes [7]. 
This peculiar organization is possible thanks to an ultra-specialized structure 
that allows the just-apposition of mitochondria to the Ca2+ release sites in the ER 
[34]. This structure, called mitochondria associated membrane (MAM), has been 
observed for the first time in the 90s [35], and has been estimated as 5-20% of the 
total mitochondrial surface [36,30]. 
Pleiotropic roles of mitochondrial Ca2+ 
Mitochondria as cytosolic Ca2+ buffers 
Mitochondria are able to act as high capacity buffers and they can sequester 
large amounts of Ca2+ from subcellular domains. In contrast to Ca2+-binding 
proteins, mitochondria act as fixed buffers of high capacity and sequester large 
amounts of Ca2+ from sub-cellular domains [7]. 
This process influences cellular Ca2+ signals and hence cell function [1]. 
Furthermore, mitochondria can regulate the activity of Ca2+ channels: mitochondria 
buffering of Ca2+ nearby the release sites is able to prevent the Ca2+-mediated 
inhibition of the channels [37]; on the contrary, mitochondrial Ca2+ accumulation 
can prevent the further activation of Ca2+ channels, by suppressing Ca2+-dependent 
positive feedback [38].  
One of the most crucial processes, in which mitochondrial Ca2+ buffering is 
involved, is the control of Ca2+ gradients in defined cellular domains. This is 
possible thanks to a strategic cellular localization of mitochondria, as observed in 
the synaptic termini of neurons and in pancreatic acinar cells [39,40]. In both cases, 
mitochondrial Ca2+ buffering is sufficient to restrict Ca2+ waves towards the 
secretory pole of these cells.  
Mitochondrial Ca2+ regulation of cell death 
Cell death pathways are strongly affected by [Ca2+]mt [12,41]. Indeed, it is 
well established that mitochondria undergo to Ca2+ overload during several 
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physiological stresses and pathological conditions [12,41]. This causes the rapid 
collapse of the membrane potential and swelling of mitochondrial membranes, with 
consequent loss of pyridine nucleotides and cytochrome c. This process is strictly 
correlated to the bioenergetics state of the cells. Indeed, conditions of mitochondrial 
Ca2+ overload, accompanied by a bioenergetics crisis and ATP depletion, are 
followed by cell death by necrosis [42].  
Furthermore, mitochondrial Ca2+ overload is also an important trigger of 
apoptosis, as observed during ischemia-reperfusion in the heart and excitotoxicity 
in neurons [12]. Indeed, Ca2+ can directly and positively stimulate mitochondrial 
permeability transition pore (mPTP) opening [12]. mPTP opening plays a key role 
in the intrinsic pathway of apoptosis. Indeed, its opening induces cristae 
remodelling and subsequent release in the cytosol of mitochondrial-residing pro-
apoptotic factors, such as cytochrome c [43]. These events are key steps for the 
induction of caspase-dependent or -independent apoptosis. Normally, physiological 
[Ca2+]mt oscillations do not induce mPTP opening, but become effective if 
paralleled by pro-apoptotic challenges [44]. 
Mitochondrial Ca2+ regulation of cell metabolism 
The ability of mitochondria to accumulate Ca2+ is fundamental for the 
regulation of several mitochondria tasks. Indeed, mitochondrial Ca2+ is able to 
modulate ATP production by oxidative phosphorylation. This regulation is possible 
thanks to the Ca2+-dependent regulation of three key enzymes of tricarboxylic acid 
(TCA) cycle, pyruvate dehydrogenase, isocitrate dehydrogenase and α-
ketoglutarate dehydrogenase. Indeed, it has been demonstrated that a Ca2+-
dependent phosphatase can directly modulate the pyruvate dehydrogenase activity, 
while the direct binding of Ca2+ to isocitrate dehydrogenase and α-ketoglutarate 
dehydrogenase plays an important regulatory role [45]. The reactions catalysed by 
these enzymes are rate limiting steps of TCA cycle. Therefore the positive 
modulation by Ca2+ of these enzymes can reflect in a substantial increase of TCA 
cycle activity, thus in an increased feeding of ETC by NADH and FADH2. 
Moreover, the regulation of the TCA dehydrogenases is not the only 
mechanism by which mitochondrial Ca2+ regulates metabolism. Indeed, in the IMM 
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are present two aspartate/glutamate exchangers (termed aralar1 and citrin) that are 
able to sense Ca2+ thanks to EF-hand Ca2+-binding domains. As a result, 
mitochondrial Ca2+ promotes metabolite transport inside the mitochondrial matrix 
that, in turn, fuels the TCA cycle [46]. 
Altogether, mitochondrial Ca2+ entry ensures prompt induction of aerobic 
metabolism paralleled by cell stimulation and, thus, activation of ATP-consuming 
processes in the cytosol.  
The Mitochondrial Ca2+ Uniporter: molecular identity and 
structural complexity 
From the first evidence that mitochondria are able to uptake Ca2+ in the 60s, 
we had to wait 50 years before the discovery of the molecular identity of the 
mitochondrial Ca2+ uniporter [47,48]. This was made possible by a seminal 
proteomic study that allowed to compile an inventory of gene products with 
mitochondrial localization, as proven by mass spectrometry and imaging studies 
(MitoCarta) [49]. In order to find candidates that fulfill the requirements to be the 
mitochondrial calcium uniporter, the MitoCarta database was examined with 
unbiased search constraints, crossing several criteria: (i) ubiquitous expression in 
mammalian tissues; (ii) a sequence compatible with that of a channel (i.e. with at 
least 2 putative transmembrane regions); (iii) presence in those organisms in which 
mitochondrial Ca2+ transport with the properties of MCU was reported and iv) 
absence in Saccaromices cerevisiae that shows no ruthenium red-sensitive 
mitochondrial Ca2+ uptake. Through this bioinformatic analysis, in 2011 our and 
Mootha’s laboratories identified a protein, encoded by the CCDC109A gene, which 
satisfies all the requirements to be the bona fide mitochondrial calcium uniporter 
[47,48]. 
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The pore forming subunits  
MCU: the mitochondrial Ca2+ channel  
CCDC109A was demonstrated to be the long sought mitochondrial calcium 
uniporter (MCU). Indeed, its overexpression is sufficient to strongly induce 
mitochondrial Ca2+ uptake upon cell stimulation and coherently its knockdown 
drastically abolishes mitochondrial Ca2+ uptake [47,48]. In addition, some insight 
into channel function were obtained, as negatively charged residues of the amino 
acid sequence separating the two transmembrane domains of the MCU were shown 
to be required for channel activity [47] and, furthermore, ruthenium red-binding 
sites were mapped in the same region [48].  
Importantly, De Stefani and colleagues demonstrated that CCDC109A is 
necessary and sufficient to mediate mitochondrial Ca2+ uptake. Indeed, purified 
CCDC190A formed a high selective Ca2+ channel in planar lipid bilayer 
experiments. Moreover, the electrophysiological properties of the newly identified 
protein, matched those previously described in isolated mitochondria, and the Ca2+ 
current could be inhibited by ruthenium red and gadolinium, two well-known 
inhibitors of the MCU [47]. All together, the genomic, physiological, biochemical 
and pharmacological data firmly established CCDC109A as the pore-forming 
subunit of the mitochondrial Ca2+ uniporter and, from that time on, the name of 
CCDC109A was changed in Mitochondrial Calcium Uniporter, MCU.  
Figure 1 - Schematic representation of the mitochondrial calcium uniporter complex  
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In line with the pleiotropic roles of mitochondrial Ca2+ signalling, these 
works demonstrated that MCU exists in a large protein complex (~480 kD) [48], 
suggesting that many other proteins contribute to channel formation. Indeed, in the 
following years, several other components of MCU complex were identified 
(Figure 1). 
MCUb: the dominant-negative regulator of MCU  
Homology search with MCU protein sequence of the MitoCarta database 
identified a related gene (CCDC109B), named MCUb, located on Mus musculus 
chromosome 3 (chromosome 4 for the Homo sapiens orthologue) [50]. MCUb is 
present in vertebrates but absent in other organisms in which MCU is present (e.g., 
plants, kinetoplastids, Nematoda, and Arthropoda) and shares 50% of similarity 
with MCU. MCUb is characterized by two transmembrane domains similar in 
sequence to MCU, although some conserved differences in the primary sequence 
are present that prevent MCUb from forming a Ca2+-permeable channel, thus acting 
as a dominant-negative subunit [50]. Thus, the incorporation of this protein in the 
MCU complex is sufficient to prevent mitochondrial Ca2+ uptake as shown in 
experiments in cell culture and in planar lipid bilayer. Interestingly, MCUb/MCU 
expression ratio varies greatly between tissues, suggesting that it might contribute 
to the spatiotemporal control of mitochondrial calcium uptake [50]. 
EMRE: the essential MCU regulator 
The last player discovered as fundamental component of MCU complex is 
EMRE (“essential MCU regulator”, previously known as C22orf32). It was 
identified through SILAC-based quantitative mass spectrometry of affinity-purified 
MCU complexes [51]. EMRE is a 10 kDa protein, present only in metazoan. It is 
composed of a single transmembrane domain that spans the IMM and possesses a 
highly conserved C-terminus rich in aspartate residues. Silencing of EMRE 
completely abrogates MCU activity in cells, even though MCU expression and 
oligomerization is preserved. This data is in contrast with experiments performed 
in our laboratory that show that MCU is sufficient to give rise to Ca2+ currents in 
planar lipid bilayer [47]. Interestingly, it was proposed that EMRE is required for 
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the interaction of MCU with MICU1 and MICU2, fundamental regulators of the 
channel (see below), since silencing of EMRE prevents MICU1 and MICU2 to 
coimmunoprecipitate with MCU [51]. However, this data is in contrast with bilayer 
experiments that showed that MICU1 is sufficient to induce MCU channel activity 
[52].  
It is important to notice that MCU and MICU1 are conserved in plants, fungi 
and protozoa where EMRE is not present. Coherently, the same authors 
demonstrate that, when expressed in yeast, Dictyostelium discoideum MCU 
homologue conducts Ca2+ in the absence of an EMRE homologue while, in these 
systems, human MCU requires the presence of EMRE to act as a functional channel 
[53]. Interestingly, it has been recently shown, by patch-clamp experiments, that 
MCU responds to mitochondrial matrix [Ca2+] through EMRE that thus acts as 
sensor of matrix [Ca2+]. This function requires conserved acidic residues in the 
matrix-localized carboxyl tail of EMRE [54].  
Given these contradictory data, further experiments are required to clarify 
the role of EMRE. 
The regulatory subunits 
One of the key features of mitochondrial Ca2+ uptake is the sigmoidal 
response to extra-mitochondrial [Ca2+] (Figure 2). In resting conditions, 
Figure 2 – Schematic diagram of cooperative activation of mitochondrial Ca2+ uptake 
Mitochondrial Ca2+ concentration ([Ca2+]mt) dependence on cytosolic Ca2+ levels ([Ca2+]cyt). Ca2+
accumulates into mitochondria with a very low rate at low [Ca2+]cyt, thanks to the activity of the gatekeeper of 
the channel. When the [Ca2+] in the proximity of mitochondria reaches a threshold value (>10 mM), MCU 
activity undergoes cooperative activation that dramatically increases mitochondrial Ca2+ uptake. In green is 
represented the phase in which the gatekeeper is active, in red the cooperative activation of MCU. 
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mitochondrial Ca2+ uptake is inhibited despite the huge driving force for matrix 
cation accumulation. This mechanism prevents vicious cycling for Ca2+ 
accumulation, conspicuous energy drain, morphological alterations and release of 
apoptotic cofactors [1]. On the other hand, [Ca2+]mt rapidly rises when the [Ca2+]cyt 
in the proximity of mitochondria reaches a threshold value (>10 μM) [36,55,56]. 
Given the topology of the MCU, a small loop facing the intermembrane space and 
the N- and C-termini residing in the matrix [48,57], it seemed unlikely that MCU 
itself could be responsible for this fundamental property. Thus, the existence of a 
highly sophisticated gatekeeping mechanisms was predicted, including both 
negative modulators acting at low [Ca2+] and activators able to induce Ca2+ currents 
during cell stimulation (Figure 3). 
MICU1: mitochondrial calcium uptake 1  
Even before the molecular identification of MCU, Mootha’s group 
discovered, through a bioinformatic search of the MitoCarta database followed by 
RNAi screening of the candidates, a mitochondrial protein whose expression clearly 
affects mitochondrial Ca2+ uptake. MICU1 (mitochondrial calcium uptake 1, 
formerly known as EFHA3) is evolutionarily conserved in vertebrates and in 
Figure 3 - Schematic representation of the mechanism controlling MCU activity by the MICU1-MICU2
heterodimer.  
A) In resting conditions, MICU1-MICU2 heterodimer acts as gatekeeper of the MCU, thanks to the dominant
inhibitory effect of MICU2; 
B) Upon cell stimulation, increase in Ca2+ concentration triggers a conformational change that induces the 
loss of MICU2-dependent inhibition and activates MICU1-mediated cooperative activation of the MCU. 
INTRODUCTION  
16 
 
kinetoplastids but absent in yeast. Although some report are in contrast [58], it is 
widely accepted that MICU1 localizes in the IMS [59,60].  
Importantly, MICU1 possesses two EF-hands domains and, accordingly, it 
was initially shown to be necessary for mitochondrial Ca2+ uptake since its silencing 
was shown to completely blunt mitochondrial Ca2+ uptake [61,62]. However, 
Madesh’s group demonstrated that mitochondria lacking MICU1 are constitutively 
loaded with Ca2+ [63]. It was thus hypothesized that MICU1 is fundamental to 
prevent Ca2+ uptake at low [Ca2+]cyt. Complexity was added by the study performed 
by Hajnóczky’s laboratory [59]. The gatekeeper role of MICU1 at low [Ca2+]cyt was 
confirmed, but it was also shown that, in the absence of MICU1, the cooperativity 
of mitochondrial Ca2+ uptake is lost, suggesting that MICU1 plays a dual function 
depending on [Ca2+]cyt. Coherently, studies in human patients in which loss-of-
function mutations in MICU1 gene cause a disease phenotype characterized by 
proximal myopathy, learning difficulties and a progressive extrapyramidal 
movement disorder, showed an increased mitochondrial Ca2+ load, both at basal 
[Ca2+]cyt and after spontaneous, low-frequency, transient increases of cytoplasmic 
Ca2+ levels [64]. 
The genuine MCU gatekeeper: MICU2 
All the studies discussed above preceded the identification of MICU1 
paralogs [65], MICU2 (mitochondrial calcium uptake 2, formerly known as 
EFHA1) and MICU3 (mitochondrial calcium uptake 3, formerly known as 
EFHA2), also characterized by the presence of two highly conserved EF-hand 
domains. MICU2 shares a similar tissue distribution with MICU1 and the IMS 
localization [60] and, importantly, MICU2 forms an obligate heterodimer with 
MICU1 through a dysulfide bond [52] (Figure 1). MICU2 inhibits the channel 
activity of purified MCU in planar lipid bilayer and reduces channel opening at 
resting [Ca2+]cyt in intact HeLa cells, thus ensuring minimal Ca2+ accumulation. 
Importantly, MICU2 protein stability depends on the presence of MICU1 
[52,65,66], suggesting that the loss of the gatekeeping property of MCU in MICU1 
silencing conditions [59,63] is due to the concomitant reduction of MICU2 
expression. In addition, as [Ca2+]cyt increases upon cell stimulation, Ca2+-dependent 
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conformational changes of the MICU1-MICU2 dimer release MICU2-dependent 
inhibition (Figure 3A). At the same time, MICU1 stimulates MCU activity, acting 
as the cooperative activator of the channel (Figure 3B). Accordingly, a MICU2 
mutant unable to bind Ca2+ acts as gatekeeper also in conditions of high [Ca2+]cyt, 
while, in the same conditions, the same MICU1 mutant loses the capability to 
cooperatively activate the channel [52,59].  
Other regulators of MCU 
MCU complex is emerging as one of the most sophisticated ion channel 
described so far. Indeed, beyond the subunits discussed above, some other proteins 
were indicated as MCU regulators, but they are not yet completely characterized 
and their roles are still controversial.  
As for MICU3, its specific function is still unknown. Moreover, its 
restricted expression in the CNS and skeletal muscle [65] suggests a tissue-specific 
mitochondrial Ca2+ uptake modulation that needs to be thoroughly investigated in 
the near future.  
Another protein whose role is not yet definitive is the Mitochondrial Ca2+ 
Uniporter Regulator 1 (MCUR1) (formerly known as coiled-coil domain-
containing 90A or CCDC90A) [67]. Notably, MCUR1 has an orthologous in yeast 
which lacks uniporter activity, thus pointing to an indirect function of MCUR1 in 
regulating mitochondrial Ca2+ uptake. Indeed, in yeast and human cells, the 
silencing of MCUR1 produces a specific cytochrome c oxidase (COX) assembly 
defect, decreased mitochondrial membrane potential (Ψm) that causes reduced 
mitochondrial Ca2+ uptake [68], thus arguing for an indirect regulation of 
mitochondrial Ca2+ homeostasis. However, measurements of MCU-mediated Ca2+ 
currents by patch-clamp electrophysiology of mitoplasts showed that stable 
knockdown of MCUR1 diminishes MCU Ca2+ currents without affecting Ψm [69]. 
Thus, further experiments are necessary to clarify the role of MCUR1. 
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Tissue-specific regulatory properties of MCU 
For many decades, it was unclear whether MCU-dependent Ca2+ uptake was 
comparable among different tissues and whether [Ca2+]mt could be modulated to 
respond to the different physiological needs of these tissues.  
At the beginning of the 70s, the characterization of mitochondrial Ca2+ 
uptake in isolated mitochondria highlighted significant differences in the activity of 
MCU among different tissues [70]. In the following years, the complete definition 
of this phenomenon, through biochemical studies and the use of optical approach, 
did not allow the reliable control of the experimental conditions (ΔΨ, matrix pH 
and Ca2+ gradient across the IMM). As a consequence, substantial discrepancies in 
the measurements of mitochondrial Ca2+ uptake in the same tissue were reported 
[26,71]. 
These limitations were bypassed by the outstanding work of Clapham and 
colleagues: they, for the first time, were able to record by patch-clamp the MCU 
current (IMCU) from IMM-derived mitoplasts, thus allowing the fine 
characterization of MCU electrophysiological properties [72]. In the following 
years, Kirichok and colleagues used the same approach to perform direct patch-
clamp measurements of IMCU in mitoplast derived from different tissues [3]. Their 
results led to the finding that IMCU varies greatly among tissues. Strikingly, they 
showed that heart IMCU is 30 times smaller than skeletal muscle IMCU although in 
heart 37% of the volume is occupied by mitochondria, while in skeletal muscle only 
the 5% [3]. Nonetheless, skeletal muscle and heart mitochondrial Ca2+ currents 
share the same biophysical properties. 
Despite the number of discoveries on the MCU complex components, the 
molecular basis of these differences are still poor understood. One of the most 
obvious explanation of the tissue-specificity of mitochondrial Ca2+ uptake is the 
differential expression of the MCU complex components. Indeed, several groups 
demonstrated that the expression of the members of the complex varies in different 
tissues and physiological conditions [47,48,50,61,65,66]. One of the most sticking 
example is MCUb. Indeed, MCUb/MCU ratio correlates with the Ca2+ 
measurement by patch-clamp [50]. Indeed, tissues characterized by low 
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mitochondrial Ca2+ transients, such as the heart, show a higher MCUb/MCU ratio, 
compared for example to skeletal muscle. Another MCU regulator that might 
contribute to these tissue-specific differences, that shows a peculiar tissue 
distribution is MICU3, whose expression is restricted to the central nervous system 
and, lower levels are found also in skeletal muscle [65]. 
It has been shown that one additional level of regulation of the rate of 
mitochondrial Ca2+ uptake in different tissues is represented by post-translational 
modifications of the components of the MCU complex. Indeed, Anderson and 
colleagues recently reported that MCU is phosphorylated and thus modulated by 
mitochondrial Ca2+/calmodulin-dependent protein kinase II (CaMKII), and this 
regulation is a crucial mechanism that controls stress response in heart [73]. Indeed, 
CaMKII is activated during ischemia-reperfusion, myocardial infarction and 
neurohumoral injury, suggesting that phosphorylation of MCU, and thus the 
modulation of [Ca2+]mt, can couple disease stress to mitochondrial injury [73]. In 
support to this, the analysis of the crystal structure of the MCU N-terminal domain 
(NTD) suggests that the residue S92 is a CaMKII phosphorylation site [74]. 
Nonetheless, Kirichock’s group claimed that the electrophysiological 
characterization of CaMKII modulation of MCU displayed properties that did not 
mimic those of the MCU [75]. Thus, further experiments are necessary to clarify 
the role of this regulatory mechanism on mitochondrial Ca2+ uptake. 
Recent data showed that also post-transcriptional mechanisms control the 
activity of MCU in pathological conditions. Indeed, it has been shown that specific 
miRNAs control the expression of MCU. In detail, it has been demonstrated that 
miR-25 affects mitochondrial Ca2+ uptake acting on the translation of MCU mRNA 
[76]. Through this mechanism, miR-25 reduces mitochondrial Ca2+ uptake and 
confers resistance to Ca2+-dependent apoptotic challenges. Interestingly, in human 
colon cancers and cancer-derived cells, miR-25 is overexpressed and MCU 
accordingly silenced. This result is strengthened by a recent study demonstrating 
that miR-25 can protect cardiomyocytes against oxidative stress through the 
modulation of MCU expression [77].  
Overall, the study of the mechanisms that regulate mitochondrial Ca2+ 
uptake in different tissues and physiopathological conditions are just beginning to 
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emerge. Further efforts will be necessary to define the MCU complex components 
regulatory mechanisms. 
The physiological role of mitochondrial Ca2+ uptake 
In parallel with the elucidation of the molecular identity and function of the 
components of the MCU complex, a number of studies have been performed to 
better elucidate the function of Ca2+ transport in physiological and pathological 
conditions. In just five years we have assisted to an explosion of information 
regarding mitochondrial Ca2+ flux [2], and it shown no sign of slowing any time 
soon.  
The most unexpected result was the characterization of the MCU full 
knockout mice (MCU-/-), that was created thanks to the gene trap technique [78]. 
Surprisingly, the MCU-/- mice are viable and fertile although the mitochondria of 
these animals are not able to accumulate Ca2+. Given the central role of 
mitochondrial Ca2+ in metabolic regulation, these mice were expected to die 
sometime during embryogenesis. Nonetheless, these mice are smaller than their 
wild type littermates and they only have modest defects in skeletal muscle strength. 
From a metabolic point of view, MCU-/- mice display reduced pyruvate 
dehydrogenase activity, without other major defects. Furthermore, the cells and 
tissues from these animals do not exhibit any marked protection from cell death, 
also followed by ischemia-reperfusion injury, although the mPTP opening is 
prevented [78]. These results opened a heated discussion among the scientists of 
the field, especially because the MCU-/- mice are viable only in a mixed genetic 
background, while the absence of mitochondrial Ca2+ uptake appears to be 
embryonically lethal in a pure background. Furthermore, compensatory 
mechanisms during embryonic development can not be excluded.  
This latter mechanism is supported by the study of the role of mitochondrial 
Ca2+ uptake in skeletal muscle homeostasis performed in our laboratory [79]. 
Indeed, it has been demonstrated that overexpressing and silencing MCU 
specifically in skeletal muscle few days after birth and in adulthood using 
Adenoassociated viral vectors (AAVs) induces dramatic changes in muscle 
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trophism. In detail, MCU overexpression triggers skeletal muscle hypertrophy, 
while coherently MCU silencing causes muscle atrophy. Importantly, MCU 
overexpression protects muscles from the loss of muscle mass during denervation. 
As for the mechanism, known hypertrophy pathways, like IGF1-Akt/PKB and 
PGC-1α4, are responsible for the regulation of muscle size by MCU. In addition, 
RNA microarray analyses demonstrated that MCU modulation controls global gene 
expression, thus identifying a Ca2+-dependent mitochondria-to-nucleus route that 
links mitochondrial function to the control of muscle mass [79,80]. 
Furthermore, the idea that in skeletal muscle mitochondrial Ca2+ uptake is 
fundamental for tissue homeostasis was strongly supported by the discovery of 
human patients with loss-of-function MICU1 mutations that trigger a neuronal and 
muscle pathological phenotype [64]. Altogether, these findings demonstrate that 
mitochondrial Ca2+ signalling in skeletal muscle plays an important role in muscle 
homeostasis.  
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Aim 
Mitochondria are crucial players in cell physiology, since they are the 
integration centre of several processes, ranging from ATP production to regulation 
of cell death. In our laboratory, we are focused on the study of the role of 
mitochondrial Ca2+ in cell homeostasis. 
The discovery of the mitochondrial Ca2+ uptake pore forming subunits and 
its regulatory subunits opened a new era for the study of the roles of mitochondrial 
Ca2+ in cell physiology but much is still controversial or unclear. One still 
unexplored paradigm of mitochondrial Ca2+ uptake is tissue-specificity. What is 
still obscure is whether variations of MCU activity are due to tissue-specific 
regulation of the MCU or to different tissue-specific expression of the MCU 
channel. Although several regulatory mechanisms emerged in the last years, many 
other efforts must be made to deepen the specific regulatory properties of MCU in 
the different tissues and physiopathological conditions. 
The focus of my PhD research was to investigate new tissue-specific 
regulatory processes that modulate mitochondrial Ca2+ uptake. In this regard, we 
identified and characterized an alternative splice variant of MICU1, MICU1.1. I 
took advantage from the long-standing experience of our group in the analysis of 
cellular Ca2+ signals in order to investigate the regulation of mitochondrial Ca2+ 
homeostasis mediated by MICU1.1. My data demonstrate that alternative splicing 
mechanisms play a prominent role in regulating mitochondrial Ca2+ uptake in 
excitable tissues. Further studies are necessary in order to clarify the physiological 
and pathological relevance of this new regulatory process.  
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Results 
Identification of an alternative splice variant of MICU1 
We identified an alternative splice variant of MICU1, hereafter named 
MICU1.1, during a PCR experiment to clone the murine MICU1 from a skeletal 
Figure 4– Identification of the alternative splice variant of MICU1, MICU1.1 
A) Partial schematic of the MICU1 genomic locus. In-frame inclusion of exon 5’ produces MICU1.1; 
B) Exon 5’ is a micro-exon that encodes for four amino acids; 
C) Sequence alignment of conventional MICU1 and MICU1.1 of 7 different vertebrate species. Conservative 
differences are marked in orange, sequence identity is marked in red; 
D) Domain structure of MICU1 and MICU1.1. N and C, N‐ and C‐termini, respectively; MTS, mitochondrial 
targeting signal; EF1 and EF2, two EF-hand domains; EFWQ indicates the position of the extra-exon in 
MICU1.1 primary structure. 
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muscle cDNA library. MICU1.1 sequence is deposited in the NCBI database with 
accession number NM_001291443.  
This alternative splice variant is created by the addition of an extra-exon 
(exon 5’) between exon 5 and exon 6 (Figure 4A) that encodes for four amino acids 
(EFWQ) (Figure 4B). Intriguingly, MICU1.1 is present also in humans and is highly 
conserved in vertebrates (Figure 4C), suggesting that this alternative splicing event 
may serve a physiological function. Invertebrates do not seem to express this variant 
of MICU1, at least from a screening of the NCBI database. The extra-exon of 
MICU1.1 is located in a region with unknown function, far from the two EF-hand 
domains of MICU1 (Figure 4D). Interestingly, the extra-exon is localized in a 
domain which was not resolved in the crystal structure of MICU1 [81], suggesting 
that this region of the protein might be highly flexible and probably involved in 
protein-protein interactions.  
MICU1.1 expression is restricted to brain and skeletal 
muscle 
Since MICU1.1 is highly conserved in vertebrates, we investigated whether 
it might contribute to tissue-specific regulatory properties of the MCU complex. To 
address this question, we first measured MICU1.1 mRNA expression levels in 
different tissues by Real-Time PCR. The results obtained show that, unlike MICU1 
that is ubiquitously expressed among tissues (Figure 5A and [47,65]), MICU1.1 
presents a peculiar expression. Indeed, it is expressed specifically in skeletal muscle 
and, at lower levels, brain (Figure 5B). Intriguingly, in all the other tissues analysed 
its expression is undetectable (Figure 5B). It is interesting to notice that MICU1 and 
MICU1.1 are co-expressed in brain with a 1:1 MICU1/MICU1.1 ratio while, in 
skeletal muscle, MICU1.1 is the predominant form with a 1:8 MICU1/MICU1.1 
ratio (Figure 5C), suggesting that a muscle-specific program controls mitochondrial 
Ca2+ uptake.  
To further verify the tissue expression specificity of MICU1.1, we 
performed a conventional PCR using primers spanning exon 5’ in order to 
discriminate the two isoforms by PCR products length. We thus separated the PCR 
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products in an acrylamide gel that allows to discriminate nucleic acid fragments 
that differ only for few nucleotides (Figure 6A). This experiment confirms the 
results that we obtained by Real-Time PCR and highlights the abundance of 
MICU1.1 in skeletal muscle (Figure 6A). 
With the same methodology, we also analysed the expression of MICU1.1 
in C2C12 myoblasts and myotubes (Figure 6B). Interestingly, upon myotubes 
differentiation, MICU1.1 expression arises, suggesting that the control of MICU1.1 
expression could be developmentally regulated (Figure 6B).  
Figure 5 – MICU1.1 expression in mouse tissues 
A) MICU1 relative expression levels in mouse tissues measured by Real-time PCR, normalized for 
Thioredoxin 1 (TNX1). Expression levels are normalized to brain, and presented as mean ± SD. n=4; 
B) MICU1.1 relative expression levels in mouse tissues measured by Real-time PCR, normalized for 
Thioredoxin 1 (TNX1). Expression levels are normalized to brain, and presented as mean ± SD. n=4; 
C) MICU1.1/MICU1 expression ratio among different mouse tissues (2^-ΔCt MICU1.1/ 2^-ΔCt MICU1 ratio).
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MICU1.1 subcellular localization and biochemical 
characterization 
We then decided to evaluate whether MICU1.1 localizes to mitochondria as 
MICU1. In order to study this aspect, we performed an immunofluorescence 
experiment in HeLa cells transfected for 48 hours either with MICU1 or MICU1.1 
tagged with a HA-tag (MICU1-HA and MICU1.1-HA, respectively). We detected 
the exogenous proteins thanks to the HA-tag and we used mitochondrially targeted 
red fluorescence protein (mtRFP) to identify mitochondria. We found that 
MICU1.1 specifically co-localizes with mtRFP, as well as MICU1 (Figure 7). This 
was an expected result since MICU1.1 mitochondrial targeting sequence is identical 
to that of MICU1 (Figure 7).  
We then decided to characterize MICU1.1 from a biochemical point of 
view, to verify whether this splice variant is able to interact with the other MCU 
complex components as MICU1. 
First, we evaluated the interaction of MICU1.1 with the pore forming 
subunit MCU (Figure 8A). In order to do this, we transfected HeLa cells with Flag-
tagged MCU together with either HA-tagged MICU1 or HA-tagged MICU1.1. We 
immunoprecipitated MCU-Flag with α-Flag antibodies and we immuno-blotted 
using α-HA specific antibodies, in order to detect MICU1 and MICU1.1. The 
Figure 6 – MICU1.1 expression in different mouse tissues and C2C12 cells 
A) Representative acrylamide gel of PCR products using primers spanning MICU1 extra-exon of cDNA of
different mouse tissues. MICU1.1 produces a band of 152 bp; MICU1 of 140 bp; 
B) Representative acrylamide gel of PCR products using primers spanning MICU1 extra-exon of cDNA
derived by C2C12 myoblast cells and C2C12 myotubes 7 days after differentiation. MICU1.1 produces a
band of 152 bp; MICU1 of 140 bp. 
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results show that MICU1.1 is able to interact with MCU as well as MICU1 (Figure 
8A), since the α-Flag antibody immunoprecipitated both MICU1 and MICU1.1. 
We conducted a similar experiment to evaluate the ability of MICU1.1 to 
interact with MICU2 (Figure 8B). We first performed a co-immunoprecipitation 
experiment by overexpressing Flag-tagged MICU2 in HeLa cells together with HA-
tagged MICU1 and MICU1.1. We immunoprecipitated MICU2-Flag with α-Flag 
antibodies and we analysed its interaction with MICU1 and MICU1.1 by 
immunoblotting with α-HA antibodies. We did not observe any difference between 
MICU1 and MICU1.1 in the capability to interact with MICU2 (Figure 8B).  
It has been shown that MICU1 can form homo- and heterodimers with 
MICU2 through dysulfide bonds [52]. This occurs between the cysteine in position 
465 of MICU1 and the cysteine 410 of MICU2, since mutation of these residues  
Figure 7- MICU1.1 localizes to mitochondria. 
Immunolocalization of MICU1 and MICU1.1. HeLa cells were transfected with mtRFP together with either 
pcDNA3.1, MICU1-HA or MICU1.1-HA. After 48 h, cells were fixed and immunocytochemistry was performed 
with -HA antibody followed by incubation with Alexa488-secondary antibodies as described in the Materials 
and methods section. Confocal images were taken (scale bar: 10 m) and a region is expanded to appreciate 
the mitochondrial localization (scale bar: 3 m). 
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Figure 8 – Biochemical characterization of MICU1.1 
A) Co-immunoprecipitation experiments. HeLa cells were transfected with the indicated constructs. Flag-
tagged MCU was immunoprecipitated from whole-cell lysate with a specific -Flag agarose-conjugated
antibody. The precipitated proteins were immunoblotted with -Flag and -HA antibodies; 
B) Co-immunoprecipitation experiments. HeLa cells were transfected with the indicated constructs. Flag-
tagged MICU2 was immunoprecipitated from whole-cell lysate with a specific -Flag agarose-
conjugated antibody. The precipitated proteins were immunoblotted with -Flag and -HA antibodies; 
C) Homo- or heterodimer formation. HeLa cells were harvested after 48 hours of transfection with the
indicated constructs and total proteins were extracted and subjected to western blotting analysis with -
Flag and -HA antibodies. SDS-PAGE was performed in the absence of DTT. 
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prevents the formation of the disulphide bond [52]. We thus tested the ability of 
MICU1.1 to homo- and heterodimerize with MICU2 by performing a SDS-PAGE 
in non-reducing conditions. The expected molecular weight of the homodimer is 
100 kDa, being MICU1 a 50 kDa protein, while a 95 kDa band is expected for the 
heterodimeric form, being MICU2 a 45 kDa protein. Figure 8C shows that when 
MICU1.1 is overexpressed alone is able to homodimerize and, when co-expressed 
with MICU2, the prevalent form is the heterodimer, as observed also for 
MICU1[52].   
In previous studies, it was demonstrated that MCU is present in high 
molecular weight complexes using blue native polyacrylamide gel electrophoresis 
(BN-PAGE) and western blot (WB) analysis [48,65]. To verify that MICU1.1 does 
not alter the composition and the stoichiometry of the MCU complex, we performed 
a similar experiment to assess the molecular weight of the MCU complex 
containing MICU1 and MICU1.1. For this purpose, we purified mitochondria from 
mouse skeletal muscle, where MICU1.1 is the prevalent form, and from mouse 
liver, where MICU1 is the only isoform expressed. Samples were prepared through 
tissue homogenization and subsequent differential centrifugations to isolate the 
tissue fraction enriched of mitochondria. The mitochondria fractions were then 
treated with a non-ionic surfactant (n-Dodecyl β-D-maltoside, DDM) to extract the 
mitochondrial proteins and preserving their macro-molecular complexes. The 
samples were then loaded in a BN-PAGE and protein complexes were separated by 
electrophoresis. The gel was blotted on a PVDF membrane and incubated with an 
α-MICU1 specific antibody, that can recognize both MICU1 and MICU1.1. Figure 
9A shows that the MCU complex present in skeletal muscle mitochondria, 
containing prevalently MICU1.1, does not differ from the liver complex, containing 
MICU1. To further confirm that MICU1.1 forms the same super-complexes as 
MICU1, we performed BN-PAGE of affinity-purified recombinant MICU1.1-
MICU2 heterodimers. Since MICU1-MICU2 heterodimer formation relays on a 
disulphide bond, we could not produce functional heterodimers in Escherichia coli, 
since this system can not ensure the eukaryotic post-translational modifications. 
Thus, we decided to express MICU1 together with MICU2 in eukaryotic cells. For 
this reason, we used the baculovirus/insect cells system that allows to efficiently 
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produce recombinant proteins with the appropriated post-translational 
modifications of eukaryotic cells. Thus, MICU1-MICU2 and MICU1.1-MICU2 
heterodimers were expressed in insect cells and the heterodimers were affinity-
purified thanks to a 6xHis tag fused to the recombinant proteins. After affinity-
purification, these proteins were loaded in a BN-PAGE, separated according to the 
molecular weights and immunoblotted using an α-MICU2 specific antibody. We 
observed three different protein complexes that are compatible with the dimeric, 
tetrameric and hexameric forms of MICU1-MICU2 complex (Figure 9B), on the 
basis of the predicted molecular weight of MICU1-MICU2 heterodimer (95 kDa).  
Together, these results clearly show that MICU1.1 is indistinguishable from 
MICU1 in the capability to interact with the other components of the MCU complex 
and to form high molecular weight complexes. 
 
Figure 9 – MICU1 and MICU1.1 supercomplexes characterization 
A) BN-PAGE of mitochondrial enriched fraction derived from mouse skeletal muscle and liver. The gel were
immunoblotted with α-MICU1 antibody to assess the molecular weight of the MCU complex containing 
MICU1 and MICU1.1. Skeletal muscle prevalently expresses MICU1.1, while liver only expresses MICU1;
B) BN-PAGE of MICU1-MICU2 and MICU1.1-MICU2 heterodimers purified through affinity-
chromatography from insect cell line upon baculovirus infection. The separated protein complexes were 
immunoblotted with α-MICU2 antibody. Based on predicted molecular weights, the possibly supercomplex
of dimers are indicated on the left.  
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MICU1.1 acts as a strong MCU activator at high [Ca2+]cyt  
Since MICU1.1 shows a peculiar tissue distribution and is highly conserved 
among vertebrates, we asked whether it displays a specific role in regulating 
mitochondrial Ca2+ uptake. To answer to this question, we decided to first asses the 
effect of MICU1.1 overexpression on mitochondrial Ca2+ uptake in intact HeLa 
cells. We evaluated mitochondrial Ca2+ uptake thanks to mitochondrially targeted 
aequorin upon maximal histamine stimulation (100 µM), as already performed 
[47,50,52]. It has been shown that MICU1 overexpression stimulates mitochondrial 
Ca2+ uptake when overexpressed in HeLa cells [52]. Strikingly, the overexpression 
Figure 10 - MICU1.1 acts as a strong MCU activator in stimulated intact cells 
A) [Ca2+]mt measurements in intact HeLa cells overexpressing for 24 hours the indicated constructs together 
with mitochondrially targeted aequorin. Cells were challenged with maximal histamine stimulation (100 
µM). The bar diagram (left panel) represents the mean peak ± SD. n=10. The panel on the right shows 
representative traces of the experiment. *p<0.05;  
B) [Ca2+]mt measurements in permeabilized HeLa cells overexpressing for 24 hours indicated constructs
together with mitochondrially targeted aequorin upon exposure to 400 nM [Ca2+]. On the left, bar diagram 
representing the mean [Ca2+]mt speed ± SD. The panel on the right shows representative traces of the 
experiment. Where indicated the perfusion medium was switched from IB/EGTA (Ca2+-free) to IB/Ca2+
(400 nM Ca2+). n=4, *p<0.05.  
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of MICU1.1 causes a major increase of mitochondrial Ca2+ uptake that significantly 
exceeds the one induced by the overexpression of MICU1 (Figure 10A). In order 
to selectively investigate the specific contribution of the mitochondrial Ca2+ uptake 
machinery, we decided to measure mitochondrial Ca2+ uptake speed in digitonin-
permeabilized HeLa cells. This experiment allows the evaluation of the properties 
of the mitochondrial Ca2+ uptake independently of the ER Ca2+ release and the 
formations of microdomains of high [Ca2+] in close proximity to mitochondrial Ca2+ 
channels. These experiments are performed initially by perfusing cells for 60 
Figure 11 – [Ca2+]cyt transients and membrane potential (ΔΨ) in MICU1 and MICU1.1 overexpressing cells
A. [Ca2+]cyt measurements in intact HeLa cells overexpressing for 24 hours the indicated constructs together 
with cytosolic aequorin. Cells were challenged with maximal histamine stimulation (100 µM). The bar 
diagram (left panel) represents the mean peak ± SD n=9. The panel on the right shows representative 
traces of the experiment. ** p<0.01; 
B. Hela cells, overexpressing for 24 hours the indicated constructs, were loaded with TMRM and TMRM 
fluorescence measurements were performed. Where indicated 10 μM FCCP were added. a.u., arbitrary
units. On the right, representative traces of the experiment. The bar diagram (left panel) represents the
mean ± SD, n=20. 
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seconds with EGTA-containing Ca2+-free intracellular buffer (IB/EGTA). Cells are 
then perfused with the same buffer with 50 M digitonin for 60 seconds and washed 
with IB/EGTA buffer for other 60 seconds. Ca2+ accumulation is initiated by 
switching the perfusion buffer to IB containing an EGTA-buffered [Ca2+] of 400 
nM. In line with the experiment in intact cells, MICU1.1 increases mitochondrial 
Ca2+ uptake rate by almost 50% (Figure 10B).  
We then asked whether the effect of MICU1.1 on mitochondrial Ca2+ uptake 
was secondary to changes in [Ca2+]cyt or in the driving force for Ca2+ accumulation 
(i.e. a collapse of mitochondrial membrane potential, ∆Ψ). We thus measured 
cytosolic Ca2+ transients by overexpressing in HeLa cells cytosolic aequorin 
together with MICU1 or MICU1.1 for 24 hours and we stimulated cells with 
histamine (100 µM). The greater mitochondrial response of MICU1 and MICU1.1 
overexpression is not secondary to alterations of the cytosolic response. Rather, a 
significant reduction in the cytosolic Ca2+ transient is observed both in cells 
overexpressing MICU1 and MICU1.1, most likely due to increased Ca2+ clearance 
by mitochondria (Figure 11A). 
As to the driving force for Ca2+ uptake, we measured mitochondrial 
membrane potential (∆Ψ) using the fluorescence probe tetramethylrhodamine 
methyl ester (TMRM). The overexpression of both MICU1 and MICU1.1 does not 
alter the mitochondrial membrane potential (Figure 11B), indicating that the 
increase of mitochondrial Ca2+ uptake observed is specifically due to MICU1.1-
mediated activation of MCU. 
Electrophysiological characterization of MICU1.1 
In order to study the regulatory properties of MICU1 and MICU1.1 on MCU 
channel activity, we performed a series of electrophysiological experiments taking 
advantage from a well-establish technique of planar lipid bilayer, as previously 
reported [47,50,52].  
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Recombinant MCU was prepared by in vitro expression using an eukaryotic cell-
free translation system, in order to obtain a pure MCU preparation without 
contamination of bacterial proteins. On the contrary, recombinant MICU1 and 
MICU1.1 were expressed in Escherichia coli. We removed the mitochondrial 
targeting sequence of both MICU1 and MICU1.1 (1-53) and to avoid protein 
aggregation and the first 43 amino acids after the predicted cleavage site of the MTS 
(MICU1Δ1-96 and MICU1.1Δ1-96), as previously performed for the crystallization of 
MICU1 [82]. Bacteria were lysed by French press to avoid the use of detergents 
and the proteins of interest were purified by affinity chromatography tandem to 
size-exclusion chromatography, to increase the purity of recombinant MICU1 and 
MICU1.1. The protein samples obtained by the affinity chromatography and the 
fractions obtain by gel filtration chromatography, containing the proteins of 
interest, were separated by SDS-PAGE and stained with G-250 colloidal Coomassie 
to assess the presence of contaminant proteins. Figure 12 shows that the gel  
Figure 12 – Expression and purification of recombinant MICU1 and MICU1.1 
A) SDS-PAGE stained with G250 colloidal Coomassie of MICU1. Lane 1: protein sample obtained after the 
affinity-purification. Lane 2: protein sample after gel-filtration chromatography; 
B) SDS-PAGE stained with G250 colloidal Coomassie of MICU1.1. Lane 1: protein sample obtained after
the affinity-purification. Lane 2: protein sample after gel-filtration chromatography.  
 
RESULTS  
37 
 
 
Figure 13 – MICU1 modulation of MCU activity recorded in planar lipid bilayer experiments  
A) Representative trace of in vitro expressed MCU activity recorded in 1 µM EGTA-buffered free-[Ca2+] 
solution during the application of -40 mV in the cis compartment. Dashed lines indicate the different
opening states. c: closed state; while “o” indicates different state in which the channels are opened; 
B) Amplitude histograms were obtained by analysing 60 seconds long traces. Gaussian fits of the multipeak 
histgram (red) and MCU current (green) were obtained using the Origin 7.5 software. The closed state is
indicated in the figure; 
C) Representative trace of MCU activity after the addition of purified recombinant MICU1.1, performed as 
in A; 
D) Amplitude histograms after the addition of MICU1 performed as in B.uthenium red (RuR), performed as 
in A; 
E) Representative trace of MCU activity after the addition of purified recombinant MICU1 and ruthenium 
red (RuR), performed as in A; 
F) Amplitude histograms after the addition of MICU1 and RuR performed as in B. 
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filtration chromatography fraction, that was chosen for the planar lipid bilayer 
experiments, contains only the band of predicted molecular weight of MICU1 and 
MICU1.1. 
Since we demonstrated that MICU1.1 strongly activates MCU at high [Ca2+], we 
decided to perform the planar lipid bilayer experiments in EGTA-buffered solution 
containing 1 µM free-[Ca2+]. All the experiments were begun with the recording of 
MCU activity during the application of the voltage of -40 mV to assess the 
incorporation of MCU into the planar lipid bilayer. Subsequently, MICU1 or 
MICU1.1 were added in the cis and trans compartments and changes in MCU 
activity were recorded. The experiments were concluded with the addition of the 
specific MCU inhibitor, ruthenium red (RuR) [83], that allows to identify the basal 
state with zero open channels. As already observed, MCU activity in a Ca2+ 
containing solution (1 µM) displayed a conductance of 18 pS, in accordance with 
our previous data [52]. In these conditions, in the example reported shown in Figure 
13A, 5 distinct current levels were detectable, that correspond to 5 different opened 
channels at the same time, but most of the time the measured current level 
corresponded to 2-3 opened channel levels (Figure 13A). Upon addition of the 
MICU1 to the same membrane during the same experiment, further activation of 
MCU was achieved, as possible to observe on the representative current traces: after 
addition of MICU1 the main current level corresponded to the continuous activity 
of 4 channels (Figure 13C). Finally, addition of ruthenium red to both sides 
drastically reduced channel activity (Figure 13E). In order to better evaluate the 
effect of MICU1 on MCU activity, amplitude histograms were obtained from the 
current traces before and after the addition of MICU1. These histograms show the 
number of events at a certain current value in a 60 second-long current trace (Figure 
13B, D, F). Thus, the height and the position of the peaks on the histograms give 
an indirect information about the time the channel spends in the open state with 
respect to the closed state. In these conditions, it is appreciable that MICU1 
powerfully activates MCU, since the number of open channels drastically increase 
(Figure 13D). Similar results were obtained in other 3 experiments, while in further 
2 cases addition of MICU1 to MCU in Ca2+-containing medium did not result in an 
increase of channel activity, for unknown reasons. 
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Figure 14 – MICU1.1 modulation of MCU activity recorded in planar lipid bilayer experiments  
A) Representative trace of in vitro expressed MCU activity recorded in 1 µM EGTA-buffered free-[Ca2+] 
solution during the application of -40 mV in the cis compartment. Dashed lines indicate the different
opening states. c: closed state; while “o” indicates different state in which the channels are opened;  
B) Amplitude histograms were obtained by analysing 60 seconds long traces. Gaussian fits of the multipeak 
histgram (red) and MCU current (green) were obtained using the Origin 7.5 software. The closed state is
indicated in the figure; 
C) Representative trace of MCU activity after the addition of purified recombinant MICU1.1, performed as 
in A; 
D) Amplitude histograms after the addition of MICU1.1 performed as in B; 
E) Representative trace of MCU activity after the addition of purified recombinant MICU1.1 and ruthenium 
red (RuR), performed as in A; 
F) Amplitude histograms after the addition of MICU1.1 and RuR performed as in B. 
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In the same experimental conditions, we evaluated the ability of MICU1.1 to 
modulate the MCU activity. As before, MCU conductance in Ca2+ containing 
solution is of 18 pS. In the example shown in Figure 14A, in these conditions, 3 
distinct current levels were detectable and the average number of open channels is 
2 (Figure 14A). Upon addition of MICU1.1, we achieved a very strong activation 
of MCU with 5-6 open channel levels for most of the time (Figure 14C). From the 
respective amplitude histograms, we observed that MICU1.1 strongly activates 
MCU, increasing the number of events at high open state compared with the trace 
recorded with MCU alone (Figure 14D). In the amplitude histograms not all 
separate current levels raising form the opening of 1 to 6 channels could be resolved 
because of the flickering behavior and because of the relatively low probability of 
finding all six channels open. From these histograms, it can not be fully appreciated 
whether or not MICU1.1 activates MCU in a more efficient manner compared with 
MICU1, but qualitatively (on the basis of amplitude histograms and current traces), 
this strong activatory effect was recorded in other 7 experiments.  
MICU1.1-induced mitochondrial Ca2+ uptake is not 
inhibited by the gatekeeper MICU2  
As already shown, MICU2 overexpression in HeLa cells is sufficient to 
reduce [Ca2+]mt uptake of about 20% in stimulated cells compared with control cells 
[52]. These data, indicating an inverse correlation between MICU2 levels and MCU 
activity, confirm the role of MICU2 as the authentic MCU gatekeeper (Figure 3). 
In line with the gatekeeper function of MICU2, it has been demonstrated that when 
MICU1 and MICU2 are both overexpressed, thus leading to an increase of the 
heterodimer only, the MICU1-dependent potentiation of mitochondrial Ca2+ 
responses is almost abolished [52]. We asked whether MICU2 overexpression leads 
to the same effect on MICU1.1. We thus overexpressed in HeLa cells 
mitochondrially targeted aequorin together with MICU1.1 and MICU2, thus 
leading to an increase of the heterodimer only. Strikingly, MICU2 overexpression 
fails to inhibit the increase of mitochondrial Ca2+ uptake due to the overexpression 
of MICU1.1 (Figure 15A). 
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We also wondered whether human MICU1.1 exerts the same effect on 
[Ca2+]mt. For this purpose, we cloned human MICU1 (hsMICU1), human MICU1.1 
(hsMICU1.1) and human MICU2 (hsMICU2) from a Homo sapiens skeletal muscle 
cDNA library and we measured mitochondrial Ca2+ uptake in the same conditions 
as in Figure 15A. This experiment clearly shows that also human MICU1.1 is a 
potent activator of mitochondrial Ca2+ uptake and that MICU2 is not able to inhibit 
its function (Figure 15B). 
Figure 15 – Murine and human MICU1.1-induced mitochondrial Ca2+ uptake is not inhibited by the 
gatekeeper MICU2. 
A) [Ca2+]mt measurements in intact HeLa cells overexpressing for 24 hours the indicated constructs together 
with mitochondrially targeted aequorin. Cells were challenged with maximal histamine stimulation (100 
µM). The bar diagram (left panel) represents the mean peak ± SD. n=10. On the right, representative traces 
of the experiment. *p<0.05, ***p<0.005, n.s. non-significant; 
B) [Ca2+]mt measurements in intact HeLa cells overexpressing for 24 hours human isoforms (hs) of MICU1, 
MICU1.1 and MICU2 together with mitochondrially targeted aequorin. Cells were challenged with 
maximal histamine stimulation (100 µM). The bar diagram (left panel) represents the mean peak ± SD. 
n=10. The panel on the right shows representative traces of the experiment. *p<0.05, ***p<0.005, n.s.
non-significant. 
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To further characterize this peculiar behaviour of MICU1.1, we decided to 
measure mitochondrial Ca2+ uptake speed in permeabilized HeLa cells. We thus 
performed a similar experiment of that shown in Figure 10B. The overexpression 
of MICU2 alone is sufficient to reduce the speed of mitochondrial Ca2+ uptake 
compared to control cells. The gatekeeper effect of MICU2 is particularly evident 
when MICU2 is co-expressed with MICU1. Indeed, in this condition, we observed 
that mitochondrial Ca2+ uptake speed increase due to MICU1 overexpression is 
blocked. Strikingly, when we measured mitochondrial Ca2+ uptake speed in cells 
overexpressing MICU1.1 together with MICU2, we found that mitochondrial Ca2+ 
uptake speed is further increased, far more than in cells overexpressing MICU1.1 
alone (Figure 16). 
Finally, we tested whether endogenous MICU1, together with 
overexpressed MICU1.1, is partially responsible of the observed effect. To verify 
this, we silenced endogenous human MICU1 and we rescued the knockdown by 
overexpressing either mouse MICU1 or mouse MICU1.1. The effect of MICU1 
knockdown is efficiently rescued by MICU1 transfection in HeLa cells, since in 
this condition the [Ca2+]mt peak is undistinguishable from control cells (Figure 17). 
On the other hand, MICU1 knockdown rescued by MICU1.1 transfection displays 
a [Ca2+]mt peak significantly higher compared to control cells (Figure 17), indicating 
Figure 16 – Cells overexpressing MICU1.1 together with MICU2 display a synergistic induction of 
mitochondrial Ca2+ uptake speed 
[Ca2+]mt measurements in permeabilized HeLa cells overexpressing for 24 hours the indicated constructs 
together with mitochondrially targeted aequorin upon exposure to 400 nM [Ca2+]. The panel on the right shows 
representative traces of the experiment. Where indicated the perfusion medium was switched from IB/EGTA 
(Ca2+-free) to IB/Ca2+ (400 nM Ca2+). On the left, bar diagram representing the mean [Ca2+]mt speed ± SD 
n=4. *p<0.05, ***p<0.005.  
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that the effect of MICU1.1 on mitochondrial Ca2+ uptake is independent from 
endogenous MICU1.  
We concluded that, when mitochondria sense high Ca2+ levels, MICU1.1 is 
able to act as a strong MCU activator. Surprisingly, the heterodimerization with 
MICU2 not only fails to inhibit MICU1.1, but synergistically increases 
mitochondrial Ca2+ uptake speed.  
MICU1.1 acts as gatekeeper of the MCU channel at resting 
[Ca2+]cyt 
It has been demonstrated that while at high [Ca2+]cyt the stimulatory effect 
of MICU1 allows the prompt response of mitochondria to Ca2+ signals generated in 
the cytoplasm, at low [Ca2+]cyt, the dominant effect of MICU2 largely shuts down 
MCU activity (Figure 3 and [52]). We thus asked whether also MICU1.1 is able to 
act as gatekeeper together with MICU2 in basal conditions as MICU1. To address 
this point, we performed an assay of gatekeeper reconstitution upon MCU 
overexpression in HeLa cells. To measure mitochondrial Ca2+ levels at resting 
conditions, we transfected a GFP-based Ca2+ probe targeted to mitochondria, 
4mtGCaMP6f, as already performed [52]. The GCaMP6 family is a group of 
ultrasensitive, green fluorescent indicator proteins that enable reliable detection of 
Figure 17 – Effect of MICU1.1 on mitochondrial Ca2+ uptake in HeLa cells silenced for endogenous 
MICU1.  
[Ca2+]mt measurements in intact HeLa cells transfected for 24 hours with the indicated constructs and siRNA 
together with mitochondrially targeted aequorin. Cells were challenged with maximal histamine stimulation 
(100 µM). On the left, bar diagram representing the mean peak ± SD. n=9. On the right, representative traces 
of the experiment. **p<0.01, **p<0.01, ***p<0.005, n.s. non-significant.  
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fast Ca2+ transients (excitation at 474 nm) [84]. GFP is circularly permutated in 
which the amino and carboxyl portions had been interchanged and reconnected by 
calmodulin (CaM) and the M13 domain of the myosin light chain kinase. This 
allows that, at low [Ca2+], the circularly permutated GFP exists in a poorly 
fluorescent state, that increases after CaM Ca2+ binding and subsequent protein 
structural shift. This fluorescence protein presents an isosbestic point (410 nm) in 
the excitation spectrum in which fluorescence emission is not Ca2+-dependent [84]. 
We exploited this property to normalize the traces for the probe expression: in this 
way, the ratio between 474 and 410 nm excitation wavelengths is proportional to 
[Ca2+] but independent of probe expression. Thanks to this probe, we observed that, 
when we overexpressed MCU for 24 hours, we obtained a 3 times increase of 
mitochondrial Ca2+ levels in resting conditions. This is due to the presence of a large 
number of channels without their regulators. In this condition, we tried to 
reconstitute the regulated channel by overexpressing the components of the 
gatekeeper heterodimer MICU1-MICU2. In this configuration, co-expression of 
MCU together with MICU1 failed to recover normal resting [Ca2+]mt, showing just 
Figure 18 – The dimer MICU1.1-MICU2 acts as gatekeeper of MCU in resting conditions 
A) Resting mitochondrial Ca2+ levels in HeLa cells overexpressing the indicated constructs, evaluated
through ratiometric imaging (Ex 474/410) of the mitochondrial targeted GCaMP6f. Data are presented
as mean ± SE, ***p<0.005, n=15; 
B) Resting mitochondrial Ca2+ levels in HeLa cells silenced for endogenous MICU1 and overexpressing
MICU2, MICU1 or MICU1.1, evaluated through ratiometric imaging (Ex 474/410) of the mitochondrial
targeted GCaMP6f. Data are presented as mean ± SE, ***p<0.005, n=15. 
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a modest reduction, probably due to partial MICU2 stabilization [65]. On the 
contrary, the concomitant expression of MCU, MICU1 and MICU2, which 
substantially increases MICU1-MICU2 heterodimer formation, efficiently rescues 
normal values of basal [Ca2+]mt, as already shown [52]. On the other hand, in HeLa 
cells, transfected with MCU together with MICU1.1, we did not observe any 
difference in [Ca2+]mt compared with cells overexpressing only MCU, suggesting 
that the homodimer MICU1.1, as MICU1, is not able to act as gatekeeper of MCU 
channel. When we overexpressed MCU, together with MICU1.1 and MICU2, we 
observed that mitochondrial Ca2+ levels in resting conditions return to the Ca2+ 
levels of control cells. This suggests that the heterodimer MICU1.1-MICU2 acts as 
a gatekeeper as MICU1-MICU2 at low [Ca2+]cyt (Figure 18A). 
To further verify these results, we decided to knockdown endogenous 
MICU1 using a specific siRNA in HeLa cells for 24 hours. The loss of MICU1 is 
sufficient to destabilize MICU2 proteins and thus leads MICU2 protein degradation 
[52,65]. Consequently, in this condition, we obtained the loss of the channel 
gatekeeper and, accordingly, a 6-times increase of basal mitochondrial Ca2+ levels. 
Thus, we tried to rescue the [Ca2+]mt by co-expressing MICU2, MICU1 or 
MICU1.1. MICU2, when overexpressed alone, is not able to rescue the 
mitochondrial Ca2+ levels increase of basal mitochondrial [Ca2+]. This is not an 
unexpected result since it has been shown that MICU2 can not act on MCU without 
the endogenous MICU1 [65,66]. On the contrary, we observed that the increase of 
mitochondrial basal Ca2+ levels is rescued by the overexpression of both MICU1 
and MICU1.1 (Figure 18B).  
Role of MICU1.1 in setting the threshold of mitochondrial 
Ca2+ uptake  
Overall, we demonstrated that MICU1.1 is a strong activator of MCU at 
high [Ca2+]cyt, while in resting conditions it is able to act as gatekeeper together with 
MICU2. It has been demonstrated that MICU1 controls both [Ca2+]cyt threshold and 
cooperativity of the MCU, with the latter being dependent on Ca2+ binding to the 
EF-hands domains of MICU1 [59]. Since the huge activation of MCU Ca2+ current  
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Figure 19 – Mitochondrial Ca2+ uptake kinetic at different Ca2+ concentration in MICU1.1 overexpressing 
cells 
A) [Ca2+]mt measurements in permeabilized HeLa cells overexpressing either MICU1 or MICU1.1 together
with mitochondrially targeted aequorin upon sequential exposure to crescent [Ca2+], as indicated in the 
graph. Data are presented as mean ± SD. n=4; 
B) [Ca2+]mt measurements in permeabilized HeLa cells overexpressing MICU1 and MICU1.1 together with
MICU2. Mitochondrial Ca2+ uptake is monitored thanks to mitochondrially targeted aequorin light 
emission. Cells were perfused sequentially with solutions at crescent [Ca2+], as indicated in the graph. 
Data are presented as mean ± SD. n=4; 
C) [Ca2+]mt measurements in permeabilized HeLa cells overexpressing MICU1 and MICU1.1 upon silencing 
of endogenous MICU1. Mitochondrial Ca2+ uptake is monitored thanks to mitochondrially targeted 
aequorin light emission. Cells were perfused sequentially with solutions at crescent [Ca2+], as indicated 
in the graph. Data are presented as mean ± SD. n=4. 
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upon overexpression of MICU1.1, we wondered whether this effect was mediated 
by changes in the threshold of initiation of mitochondrial Ca2+ uptake. To assess 
this, we measured mitochondrial Ca2+ uptake thanks to aequorin light emission in 
permeabilized HeLa cells. Thus, we perfused permeabilized cells sequentially with 
solutions containing increasing free-Ca2+ concentrations (from 200 nM to 600 nM), 
perfusing cells with each solution for the same period of time (30 seconds). First, 
we analyzed the effect of MICU1 and MICU1.1 overexpression in HeLa cells for 
24 hours. As observed in the previous experiment (Figure 10B), the overexpression 
of MICU1.1 induces a prompter response at each [Ca2+] compared to control cells 
and MICU1 overexpressing cells (Figure 19A).  
On the contrary, as expected, MICU2 overexpression shows a negative 
modulation on mitochondrial Ca2+ uptake speed response. This is also observed 
when we co-expressed MICU1 together with MICU2. Indeed, the reconstitution of 
the MICU1-MICU2 heterodimer abrogates the faster and higher response caused 
by the overexpression of MICU1 upon perfusion of 300 nM free-[Ca2+] solution. 
On the contrary, cells overexpressing the heterodimer MICU1.1-MICU2 present a 
sustained mitochondrial Ca2+ uptake at lower free [Ca2+] (at 200 nM free-[Ca2+] 
solution), at which control cells and cells overexpressing MICU1 together MICU2 
do not initiate mitochondrial Ca2+ uptake (Figure 19B). 
It has been recently published that mitochondrial Ca2+ uptake is regulated 
by a Ca2+-dependent remodelling of the uniporter complex [85]. In this model, the 
dimer MICU1-MICU2 associates with MCU in a Ca2+-dependent manner. Indeed, 
at low [Ca2+]cyt levels, the dimer associates with MCU, while it dissociates upon 
increases of [Ca2+]cyt [85]. We thus asked whether the huge increase of [Ca2+]mt 
caused by the overexpression of MICU1.1 together with MICU2 was due to the 
dissociation of MICU1.1-MICU2 heterodimer from MCU. If this is the case, the 
overexpression of MICU1.1 should mimic the loss of the gatekeeper. To address 
this question, we measured mitochondrial uniporter threshold in permeabilized cells 
in which endogenous MICU1 was silenced by a specific siRNA (Figure 19C). To 
perform this experiment, as in Figure 19B, we measured [Ca2+]mt in permeabilized 
HeLa cells by perfusing them sequentially with increasing free Ca2+ concentrations. 
We compared mitochondrial Ca2+ uptake of cells in silenced for endogenous 
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MICU1 for 24 hours, compared with cells in which this MICU1 knockdown was 
rescued by the overexpression of either MICU1 or MICU1.1. The results show that 
the silencing of MICU1 causes the complete loss of gatekeeper, since these cells 
display a [Ca2+]mt uptake even at very low free-[Ca2+] concentrations (200 nM) 
(Figure 19C). In line with previous results, MICU1.1 rescue affects the threshold 
of activation of MCU, shifting the threshold towards lower free-[Ca2+] (from 400 
nM to 300 nM) compared with control cells (Figure 19C). Nevertheless, the 
response starts at higher [Ca2+] than in condition of total loss of the dimer MICU1-
MICU2, suggesting that MICU1.1 does not induce the dissociation of the dimer. 
Ca2+-dependent functional regulation of the MICU 
complex 
It has been shown that MICU1 and MICU2 are able to sense Ca2+ levels 
thanks to the two EF-hand domains present in their amino acid sequence. This is 
demonstrated by the functional behaviour displayed by MICU1 and MICU2 
mutants (MICU1EFmut and MICU2EFmut, respectively) in which the EF-hand 
domains lose the capability to bind Ca2+ [52,59,66]. Since MICU1 is activated upon 
Ca2+ binding, MICU1EFmut is locked in the ‘inactive state’. As a consequence, its 
function is not affected in basal conditions when it is normally inactive while in 
conditions of high [Ca2+]cyt, MICU1EFmut loses the ability to operate as cooperative 
activator of MCU [59]. Since this Ca2+-dependent activity of MICU1, we decided 
to evaluate the effects of EF-hand domains mutations on MICU1.1 activity. We 
thus created MICU1.1EFmut-HA by mutating key residues of the two EF-hand 
domains (D237A, E248K, D427A, E438K) and we tested its effect on 
mitochondrial Ca2+ uptake in HeLa cells after 24 hours of transfection. We observed 
that MICU1.1EFmut reduces mitochondrial Ca2+ uptake of 40%, significantly less 
compared to MICU1EFmut effect (Figure 20A). However, the reduction is still 
significant if compared to control cells. On the other hand, the heterodimer 
MICU1.1EFmut-MICU2 dramatically abrogates mitochondrial Ca2+ uptake as 
MICU1EFmut-MICU2 dimer (Figure 20A). 
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We also assessed the effect of MICU2EFmut (D372A) on MICU1.1 activity. 
As already shown, this mutant is able to almost completely blunt mitochondrial 
Ca2+ uptake upon cell stimulation, since Ca2+ is unable to relieve MICU2 inhibition 
of the uniporter, regardless of Ca2+ concentration (Figure 20B and [52,66]). Co-
expression of MICU2EFmut together with MICU1 is not able to re-establish normal 
[Ca2+]mt uptake, highlighting the inhibitory role of apo-MICU2 on MCU activity 
(Figure 20B). Surprisingly, cells co-transfected with MICU2EFmut together with 
MICU1.1 display a [Ca2+]mt peak comparable with the one in control cells (Figure 
Figure 20 – Ca2+-dependent functional effects of MICU1 and MICU2
A) [Ca2+]mt measurements in intact HeLa cells overexpressing for 24 hours the indicated constructs together 
with mitochondrially targeted aequorin. Cells were challenged with maximal histamine stimulation (100 
µM). On the left, bar diagram representing the mean peak ± SD. n=5. The panel on the right shows 
representative traces of the experiment. **p<0.01, ***p<0.005, n.s. non-significant;.  
B)  [Ca2+]mt measurements in intact HeLa cells overexpressing for 24 hours the indicated constructs together 
with mitochondrially targeted aequorin. Cells were challenged with maximal histamine stimulation (100 
µM). On the left, bar diagram representing the mean peak ± SD. n=5. The panel on the right shows 
representative traces of the experiment. ***p<0.005, n.s. non-significant. 
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20B), suggesting that MICU1.1 activatory effect is less affected by MICU2 
inhibition than conventional MICU1. 
MICU1.1 behaviour depends on the residues that compose 
the extra-exon  
We next wondered whether the amino acids that compose the extra-exon are 
responsible for MICU1.1 peculiar behaviour. To address this issue, we decided to 
create some MICU1.1 mutants of the extra-exon residues. First, we substituted each 
residue with alanine (MICU1.1E182A, MICU1.1F183A, MICU1.1W184A, and 
MICU1.1Q185A) in order to verify which of the four amino acids defines the strong 
activatory function of MICU1.1. We thus tested the effect of these mutants on HeLa 
cells mitochondrial Ca2+ uptake when co-expressed with MICU2 for 24 hours since 
in this condition we observed the most dramatic effect of MICU1.1. This allows us 
to detect more efficiently any effect of these mutants. Figure 21A clearly shows that 
all these mutants, when overexpressed together with MICU2, behave 
indistinguishably from MICU1.1 wild-type. 
We then decided to evaluate the effects of MICU1.1 mutants in which we 
deleted one by one each of the residues of the extra-exon (MICU1ΔE182, 
MICU1ΔF183, MICU1ΔW184 and MICU1ΔQ185). We verified their ability to modulate 
[Ca2+]mt uptake when co-expressed together with MICU2 in HeLa cells. Only the 
deletion of tryptophan causes a statistically significant difference in mitochondrial 
Ca2+ uptake compared to MICU1.1. However,  this mutant increases dramatically 
mitochondrial Ca2+ uptake compared to MICU1 (Figure 21B). Overall, these data 
suggest that no residues of extra-exon are indispensable for the peculiar behaviour 
of MICU1.1. 
To further verify the causative role of the extra-exon in defining the 
activatory properties of MICU1.1, we created another mutant in which we 
substituted all four residues in alanine (MICU1.1E182A, F183A, W184A, Q185A, hereafter 
indicated as MICU1.1AAAA). We expected that if this extra-exon has a role in 
defining the peculiar activatory property of MICU1.1, this mutation will completely 
abrogate the differences between MICU1.1 and MICU1. Thus, we evaluated the 
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capability of MICU1.1AAAA together with MICU2 to modulate mitochondrial Ca2+ 
uptake in HeLa cells after 24 hours of transfection (Figure 22A). As expected, this 
mutant evokes a mitochondrial Ca2+ uptake comparable with that observed in cells 
transfected with MICU1 together with MICU2 (Figure 22A).  
We characterized also the MICU1.1AAAA mutant in terms of mitochondrial 
Ca2+ uptake kinetic in permeabilized HeLa cells by perfusing them sequentially 
with different solutions at increasing free-[Ca2+], as performed above (Figure 19). 
First, we overexpressed MICU1.1AAAA alone to assess the effect of MICU1.1AAAA 
Figure 21 – Single mutations and deletions of the extra-exon amino acids do not alter MICU1.1 functional
properties  
A) [Ca2+]mt measurements in intact HeLa cells overexpressing for 24 hours the indicated constructs together 
with mitochondrially targeted aequorin. Cells were challenged with maximal histamine stimulation (100 
µM). On the left, bar diagram representing the mean peak ± SD. n=4. On the right, representative traces 
of the experiment. ***p<0.005; 
B) [Ca2+]mt measurements in intact HeLa cells overexpressing for 24 hours the indicated constructs together 
with mitochondrially targeted aequorin. Cells were challenged with maximal histamine stimulation (100 
µM). On the left, bar diagram representing the mean peak ± SD. n=5. *p<0.05. The panel on the right 
shows representative traces of the experiment. ***p<0.005. 
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Figure 22 – The substitution mutant MICU1.1AAAA alters MICU1.1 functional properties in intact and 
permeabilized cells 
A) [Ca2+]mt measurements in intact HeLa cells overexpressing MICU1.1AAAA together with MICU2 and with 
mitochondrially targeted aequorin. Cells were challenged with maximal histamine stimulation (100 µM).
On the left, bar diagram representing the mean peak ± SD. n=6. On the right, representative traces of the
experiment. **p<0.01, ***p<0.005; 
B) [Ca2+]mt measurements in permeabilized HeLa cells overexpressing either MICU1.1AAAA, MICU1.1 or 
MICU1 with mitochondrially targeted aequorin upon sequential exposure to crescent [Ca2+], as indicated 
in the graph. Data are presented as mean ± SD. n=4;  
C) [Ca2+]mt measurements in permeabilized HeLa cells overexpressing MICU1.1AAAA together with MICU2 
and mitochondrially targeted aequorin. Cells were perfused sequentially with solutions at crescent [Ca2+], 
as indicated in the graph. Data are presented as mean ± SD. n=4. 
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homodimer in modulating mitochondrial Ca2+ uptake (Figure 22B). In this 
condition, the kinetic profile of MICU1AAAA is indistinguishable from MICU1 
(Figure 22B). We then verified the effect of this mutant when overexpressed 
together with MICU2 in HeLa cells. Also in this condition, we did not observe any 
difference with cells overexpressing MICU1-MICU2 (Figure 22C). 
In conclusion, although single mutations of the extra-exon did not show a 
significant difference in MICU1.1 activity, the substitution of all four residues 
confirms that this domanin is responsible of the activatory function of MICU1.1  
MICU1.1 expression levels during the progression of 
denervation atrophy 
In order to establish whether the expression levels of MICU1.1 is affected 
in physiopathological conditions and since MICU1.1 is expressed prevalently in 
skeletal muscle, we focused our attention on skeletal muscle denervation atrophy. 
Figure 23 – MCU complex component expression levels during the progression of denervation atrophy. 
A) MCU, MICU1 and MICU2 relative mRNA expression levels in control mouse tibialis anterior (TA)
muscles TA muscles denervated for 3 days measured by Real-time PCR, normalized for GAPDH.
Expression levels are normalized for GAPDH and quantification data are expressed with ΔCt methods.
Data are presented as mean ± SD. n=4 ***p<0.005;  
B) MICU1.1/MICU1 expression ratio of control TA muscles and TA muscles after 3 and 7 days after
denervation (2^ΔCt MICU1.1/ 2^ΔCt MICU1 ratio). Expression levels are normalized for GAPDH. Data
are presented as mean ± SD. n=4 ***p<0.005.  
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We analysed the expression of the uniporter complex components during the 
progression of denervation of tibialis anterior (TA) mouse muscles. For this 
purpose, we unilaterally cut the sciatic nerve of 4 mice for each condition to induce 
atrophy of the hindlimb and we collected TA muscles 3 and 7 days after 
denervation. It is well established that cutting the sciatic nerve produces significant 
atrophy of TA muscles in mouse models [86,87], and this catabolic state involves a 
precise transcriptional program [88–90]. In line with this, we found that the 
components of MCU are differentially regulated during denervation atrophy. 
Indeed, while the expression of pore-forming subunit MCU is not perturbed, 
MICU1, which comprises both MICU1 and MICU1.1, is strongly induced and, at 
lower extent, also MICU2 expression increases (Figure 23A). Noteworthy, in this 
condition, the ratio between MICU1.1 and MICU1 increases dramatically during 
the progression of atrophy, starting from a ratio of 8:1 in control muscles to a ratio 
of 14:1 at 7 days after the cut of the sciatic nerve (Figure 23B). 
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Discussion 
The ability of mitochondria to accumulate Ca2+ is fundamental for the 
regulation of several biological processes. Importantly, mitochondrial Ca2+ uptake 
enables these organelles to shape cytosolic Ca2+ transients, resulting in 
mitochondrial control over intracellular Ca2+ signalling. Moreover, mitochondrial 
Ca2+ has a pivotal role in cell survival, since it has already been demonstrated that 
mitochondrial Ca2+ overload is an important trigger of apoptosis [1]. 
Another crucial function of mitochondrial Ca2+ is the modulation of ATP 
production by oxidative phosphorylation. Indeed, it has been demonstrated that 
Ca2+ can modulate mitochondrial metabolism [45]. This concept was strengthened 
by the evidence that mitochondrial Ca2+ controls the rate of autophagy, since it has 
been shown that decreased mitochondrial Ca2+ uptake results activation of AMPK, 
which activates pro-survival macroautophagy [91]. Altogether, these results 
strongly support the role of  mitochondrial Ca2+ uptake in regulating essential 
cellular processes such as mitochondrial respiration and maintenance of normal cell 
bioenergetics.  
Furthermore, it is known for many decades that the MCU complex exhibits 
tissue-specific properties. This concept was made stronger by experiments of direct 
patch-clamp recordings of the Ca2+ current through MCU (IMCU) in mitoplasts 
derived from mitochondria of different tissues [3]. The molecular basis of these 
differences are still poorly understood and how this complex machinery is 
modulated in different tissues and physiopathological conditions is still an open 
question. One sticking and still mysterious example of this regulation is that MCU 
current (IMCU) in mouse heart is extremely lower than in other mouse tissues [3]. In 
particular, in heart, IMCU is 30 times smaller than in skeletal muscle although in 
heart mitochondria occupy the 37% of the volume, while in skeletal muscle only 
the 5%.  
Tissue-specific differential expression of the components of the MCU 
complex as well as post-translational and post-transcriptional modifications could 
explain the different Ca2+ accumulation in different tissues. Indeed, it has been 
shown that all these mechanisms act on the regulation of MCU activity in different 
tissues in physiological and pathological conditions [50,76,77,92]. 
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Here we found an additional new regulatory mechanism modulating 
mitochondrial Ca2+ uptake: alternative splicing. Indeed, during PCR experiments to 
clone murine MICU1 from a skeletal muscle cDNA library, we discovered an 
alternative splice isoform of MICU1 that we named MICU1.1. This variant is 
characterized by the addition of a micro-exon coding for 4 amino acids (EFWQ) 
located in the intron between exon 5 and exon 6.  
We decided to study in detail this splice variant first because we found that 
MICU1.1 is present in humans and conserved in all vertebrates and second because 
other crucial modulators of Ca2+ homeostasis are subjected to alternative splicing 
events. Indeed, it has been recently discovered an alternative splice variant of 
STIM2, a pivotal player in the Store-Operated Ca2+ Entry (SOCE), in which a 
micro-exon insertion in STIM2 mRNA disables this variant from activating Orai1 
[93,94]. 
Interestingly, MICU1.1 shows a peculiar tissue expression. Indeed, while 
MICU1 is ubiquitously expressed, MICU1.1 expression is restricted to tissues with 
the greatest levels of mitochondrial Ca2+ uptake, skeletal muscle and, at lower 
levels, brain. Strikingly, in skeletal muscle, MICU1.1 is the predominant isoform, 
suggesting that in this tissue it might play a peculiar function in regulating 
mitochondrial Ca2+ uptake.  
We decided to characterize this splice variant first by evaluating its ability 
to interact with the other pore complex components. We observed no differences in 
the ability of MICU1.1 to interact with MCU and with MICU2. Furthermore, 
MICU1.1 can heterodimerize with MICU2 as well as MICU1 and it can also give 
rise to high molecular weight complexes of the same molecular weights as MICU1. 
Thus, MICU1.1 seems indistinguishable form MICU1 from the biochemical point 
of view (Figure 1). Noteworthy, the region in which the extra exon is inserted has 
not been resolved in the crystal structure of MICU1 [95], suggesting that is a 
flexible region possibly involved in interaction with known or unknown MCU 
complex components.  
We then asked what was the effect of MICU1.1 on mitochondrial Ca2+ 
uptake. It has recently been demonstrated that MICU1 is the MCU activator at high 
[Ca2+]cyt and for the prompt response of mitochondria to [Ca2+]cyt increases (Figure 
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3B). On the other hand, MICU2 is MCU genuine gatekeeper that inhibits MCU 
activity at low [Ca2+]cyt [52], ensuring minimal Ca2+ accumulation in the presence 
of a huge driving force for cation accumulation, thus preventing the deleterious 
effects of Ca2+ cycling and matrix overload (Figure 3A). 
Surprisingly, MICU1.1, when overexpressed in HeLa cells, causes a major 
increase of mitochondrial Ca2+ uptake upon histamine stimulation that exceeds the 
one induced by the overexpression of MICU1. This effect is specific, as membrane 
potential is not perturbed by the overexpression of MICU1.1 and cytosolic Ca2+ is 
rather reduced, most likely due to increased Ca2+ clearance by mitochondria, as 
already observed for the overexpression of MCU [47]. We also confirmed that 
human MICU1.1 exerts the same activatory role on mitochondrial Ca2+ uptake.  
We also checked whether endogenous MICU1 interferes with MICU1.1 
effect, being the two variants able to form dimers. In MICU1 silenced HeLa cells, 
MICU1.1 overexpression exerts the same activatory effect on MCU.  
Enhanced mitochondrial Ca2+ uptake mediated by MICU1.1 was confirmed 
also in permeabilized cells. This experiment allows the evaluation of mitochondrial 
Ca2+ uptake independently from Ca2+ released from the endoplasmic reticulum and 
the formation of microdomains of high [Ca2+] in close proximity to mitochondrial 
Ca2+ channels. Strikingly, MICU1.1 overexpression is accompanied by an increase 
of about the 50% of mitochondrial Ca2+ uptake speed compared to cells 
overexpressing MICU1.  
Since this strong activatory effect of MICU1.1, we decided to better characterize 
the ability of MICU1.1 to modulate MCU activity trying to recapitulate the MCU 
machinery in vitro in planar lipid bilayer. These experiments demonstrate that 
MICU1.1 acts as a strong MCU activator in these conditions. Surprisingly, we did 
not observe major differences between MICU1 and MICU1.1. This could suggest 
that MICU1.1 is important in the threshold definition of MCU, reason why we did 
not detect a significant difference. Other experiments have to be performed to fully 
characterized MICU1.1, analyzing the behavior of MICU1.1 when heterodimerized 
with MICU2, a condition in which, differently from MICU1, we observed a 
cooperative activation of the MCU activity. 
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It is known that in physiological conditions the heterodimer MICU1-
MICU2 is the prevalent form [52]. We thus studied the effect of this new splice 
variant in a more physiological condition. We thus overexpressed MICU1 and 
MICU1.1 together with MICU2 in HeLa cells in order to shift the balance towards 
the MICU1-MICU2 and MICU1.1-MICU2 heterodimers. It has been demonstrated 
that MICU2 prevents the mitochondrial Ca2+ uptake increase due to MICU1 [52] 
but, strikingly, MICU2, when overexpressed with MICU1.1, is unable to inhibit the 
induction of mitochondrial Ca2+ uptake caused by MICU1.1 overexpression. 
Moreover, in permeabilized cells mitochondrial Ca2+ uptake speed is not decreased, 
as observed overexpressing MICU1-MICU2 heterodimers but, unexpectedly, it 
increases far more than in cells transfected only with MICU1.1, suggesting that 
MICU2 synergistically activates mitochondrial Ca2+ uptake when bound to 
MICU1.1. Overall, we can conclude that MICU1.1-MICU2 heterodimer acts as a 
strong activator of the MCU complex in conditions of high [Ca2+]. 
Since it was shown that MICU2 acts as the gatekeeper of the channel at low 
[Ca2+]cyt (Figure 3A) and our data demonstrate that the MICU1.1-MICU2 dimer 
acts as a strong activator of the channel at high [Ca2+]cyt, we decided to assess 
whether the MICU1.1-MICU2 heterodimer is able to act as gatekeeper of the 
channel in resting conditions. Surprisingly, the heterodimer MICU1.1-MICU2 is 
able to act as gatekeeper of the channel as well as MICU1-MICU2 heterodimer. We 
demonstrated this property by two gatekeeper reconstitution assays in which we 
analysed the effect of the different modulators in regulating the activity of free 
MCU oligomers, not bound to both MICU1 and MICU2. We obtained this by either 
overexpressing MCU, which favours the condition in which the channel is present 
in the mitochondrial membrane without its gatekeeper and by silencing MICU1, 
condition that destabilizes also MICU2 protein. Both this approaches clearly 
showed that also the MICU1.1-MICU2 dimer causes minimal Ca2+ uptake at low 
[Ca2+]cyt.  
We then tried to deepen our knowledge of the mechanism by which the 
MICU1.1-MICU2 dimer strongly activates MCU at high [Ca2+]cyt. One possible 
mechanism is that the MICU1.1-MICU2 dimer cooperatively activates 
mitochondrial Ca2+ uptake at lower [Ca2+]cyt. We thus hypothesized that the 
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MICU1.1-MICU2 dimer can shift to the left the [Ca2+]cyt mitochondrial Ca2+ uptake 
curve (Figure 2). To analyse this aspect, we performed an experiment in 
permeabilized conditions in which, after digitonin treatment, mitochondria were 
subjected to crescent [Ca2+]. In these conditions, as hypothesized, mitochondria 
overexpressing MICU1.1 and MICU2 take up Ca2+ at [Ca2+] at which mitochondria 
transfected with the MICU1-MICU2 heterodimer show only a mild uptake.  
These results highlight the possible role of the prevalent expression of 
MICU1.1 in excitable tissues where Ca2+ plays a pivotal functional role. We 
demonstrated that, at resting conditions, this splice isoform does not induce Ca2+ 
entry inside mitochondria, thus ensuring protection from Ca2+ overload and cell 
death but, upon cell stimulation, it ensures a fast and high Ca2+ entry in 
mitochondria even at low [Ca2+]cyt. Intriguing, this can be an important mechanism 
in excitable tissues where fast Ca2+ transients occur [96–98]. Indeed, we can 
speculate that in skeletal muscle the prevalent expression of MICU1.1 allows a 
prompt response of mitochondria metabolism, ensuring a sustained ATP production 
during resistance and strenuous exercise. 
We also analysed the Ca2+-dependent regulation of the MICU1.1-MICU2 
heterodimer. For this purpose, we mutated the EF-hand motives of MICU1.1 
(MICU1.1EFmut) in order to prevent Ca2+ binding to this protein. As shown also for 
MICU1 [52,59,66], these domains are fundamental for MICU1.1 activity in 
stimulated cells, since their mutation completely abrogates MICU1.1 activity. We 
also overexpressed MICU1.1 with a MICU2 mutant whose EF-hands are unable to 
bind Ca2+ (MICU2EFmut). It has been shown that this mutant is capable of inhibiting 
Ca2+ uptake also in conditions of high [Ca2+]cyt and to prevent MICU1-dependent 
activation of MCU in stimulated cells. Interestingly, MICU1.1 is less affected by 
the dominant-negative effect of MICU2EFmut, compared to MICU1. This result 
suggests that MICU1.1 regulation of MCU activity is partially independent from 
MICU2. Indeed, while MICU1 is subjected to a tight regulation by MICU2 at high 
[Ca2+], MICU1.1 seems to act, at least in part, independently from the gatekeeper 
function of MICU2. 
We also asked whether one of the four additional residues was required for 
MICU1.1 activity. Our data demonstrate that neither the single substitution with 
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alanine nor the deletion of single amino acids influence significantly the activity of 
MICU1.1. Only the substitution of all the four amino acids of the extra-exon with 
alanine is able to blunt MICU1.1 activity, recapitulating MICU1 function. Further 
studies are necessary in order to understand whether double or triple mutations of 
the amino acids composing the extra exon can affect the peculiar behaviour of 
MICU1.1 and possibly, since MICU1 crystal structure is available [82], using 
bioinformatics analysis, we might predict the three-dimensional structure of this 
domain. 
Overall, the newly identified alternative splice variant of MICU1 represents 
a novel mechanism of regulation of mitochondrial Ca2+ uptake in excitable tissues 
that contributes to explain the tissue-specific regulatory properties of MCU. Indeed, 
the peculiar expression profile of this splice variant correlates with the highest 
mitochondrial Ca2+ uptake currents [3].  
Our hypothesis is that, in skeletal muscle, mitochondrial Ca2+ uptake is more 
efficient in order to sustain the huge ATP consumption needed for contraction. In 
the future, we will characterize the functional properties of this new isoform in 
regulating mitochondrial Ca2+ uptake in physiological contests. Indeed, we found 
that C2C12 mouse muscle cell line expresses this splice variant only upon myotube 
differentiation. We will take advantage from this system to understand the 
physiological role of this alternative splice variant in the skeletal muscle 
homeostasis in vitro. Specifically, we will modulate the expression of this variant 
and measure ATP production and oxygen consumption rate.  
We will also analyse mitochondrial Ca2+ dynamics in skeletal muscle in 
vivo. First, we will evaluate the effects of an acute silencing of MICU1.1 and 
MICU2 through specific shRNA delivered by adeno-associated viruses (AAVs). 
Simultaneously, we will carry out experiments in which we will assess the effects 
of overexpressing MICU1.1 together with MICU2 by AAVs infection. We will 
evaluate the effects of these treatments on muscle trophism and on known signalling 
pathways involved in atrophy and hypertrophy.  
Furthermore, we will specifically substitute the expression of MICU1.1 with 
MICU1 in skeletal muscle. To do this, we plan to remove MICU1.1 extra-exon by 
CRISPR/Cas9-mediated non homologous end joining (NHEJ) in postnatal muscle 
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tissues, following delivery of gene editing components using AAVs, as already 
performed [99]. In detail, we will produce AAV viral particles expressing Cas9 that 
we will inject in tibialis anterior mouse muscles together with an AAV expressing 
the guide RNA and GFP in order to visualize the infected fibers. CRISPR/Cas9-
mediated NHEJ will thus create an internal genomic deletion to bypass the 
transcription of the MICU1.1 extra-exon. In this way, only MICU1 will be 
expressed and thus we will study the specific role of MICU1.1 in skeletal muscle. 
This approach has been recently used with success to correct the DMD mutations 
in postnatal muscle tissues in mdx mouse model [99].  
Strong preliminary data support the hypothesis that MICU1.1 modulation 
of [Ca2+]mt can be a major determinant of skeletal muscle homeostasis. First, it has 
been recently shown that the lack of MICU1, due to loss-of-function mutations 
preventing its expression, leads to mitochondrial Ca2+ overload under basal 
conditions, and this results in an autosomal recessive human disease with muscle 
phenotype characterized of proximal muscle weakness and learning difficulties 
[64]. Importantly, muscle weakness is accompanied by moderately to grossly 
elevated serum creatine kinase levels. In line with the symptoms, muscle biopsies 
showed myopathic features, with diffuse variation in fiber size, increased frequency 
of internal and central nuclei, and clusters of regenerating fibers. Second, it was 
recently demonstrated that mitochondrial Ca2+ has a dramatic trophic effect that 
impinges on two major hypertrophic pathways of skeletal muscle, PGC-14 and 
IGF1-Akt/PKB [79]. Microarray analyses demonstrated that MCU modulation 
controls global gene expression, thus identifying a Ca2+-dependent mitochondria-
to-nucleus route that links mitochondrial function to the control of muscle mass. 
Third, MCU knockout mice show clear metabolic and functional alterations of 
skeletal muscle [78]. 
Further evidence in support of the central role of mitochondrial Ca2+ in 
muscle homeostasis is provided by the observation that the components of the 
mitochondrial Ca2+ uniporter are differentially regulated during the catabolic state 
induced in TA mouse muscles by sciatic nerve dissection. Strikingly, the expression 
of the pore-forming subunit MCU is not perturbed, while the expression of the 
regulatory subunits MICU1 (which comprises both MICU1 and MICU1.1) and 
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MICU2 are significantly induced during the progression of atrophy. This result 
strongly suggests that mitochondrial Ca2+ modulation plays an important role in 
skeletal muscle fibers adaptation to physiological and pathological stresses. 
Noteworthy, in this condition the ratio between MICU1.1 and MICU1 increases 
dramatically, starting from a ratio of 8:1 to a ratio of 14:1 at 7 days after the cut of 
the sciatic nerve, suggesting a precise control of splicing events in pathological 
conditions of skeletal muscle. 
Overall, these data demonstrate a muscle-specific mitochondrial Ca2+ 
uptake machinery with a presumably unique function and further experiments have 
to be performed to clarify its physiological and pathological relevance. 
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Materials and methods 
Legend of abbreviation 
bp = base pair; 
cDNA = DNA complementary to RNA;  
DDM = n-dodecyl-β-D-maltoside; 
DMEM = Dulbecco’s modified Eagle’s medium;  
FBS = fetal bovine serum; 
g = gravity;  
g = grams; 
HCl = hydrochloric acid;  
KCl = potassium chloride;  
HS = horse serum; 
Hz = Hertz 
KH2PO4 = potassium phosphate; 
M = molar; 
min = minutes;  
mL = milliliters;  
ms = milli seconds; 
NaCl= sodium chloride; 
NaOH = sodium hydroxide;  
Na2HPO4 = sodium hydrogen phosphate; 
nm = nanometers;  
NaHCO3 = sodium bicarbonate; 
PBS = Phosphate-buffered saline; 
PCR = polymerase chain reaction; 
rpm = revolutions per minute; 
RT = room temperature;  
SDS = sodium dodecyl sulfate; 
s = seconds;  
TA = tibialis anterior;  
PFA = paraformaldehyde; 
L = microliters; 
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RNA extraction, reverse transcription, and quantitative 
Real-Time PCR 
For the expression analysis of MICU1 and MICU1.1 in mouse tissues, adult 
male CD1 mice (28-30 g) were used. Skeletal muscle (tibialis anterior (TA)), heart, 
brain, spleen, lung, liver, kidney and visceral fat were excised from three age-
matched animals. Total RNA was extracted through mechanical tissue 
homogenization in TRIZOL reagent (Thermo Fisher Scientific) following 
manufacturer instructions. The RNA was quantified with Nanodrop (Thermo Fisher 
Scientific) and 1 µg of total RNA of each samples was retro-transcribed with the 
cDNA synthesis kit SuperScript II (Thermo Fisher Scientific). Oligo(dT)12-18 
primer (Thermo Fisher Scientific) were used as a primer for first stand cDNA 
synthesis with reverse transcriptase. The obtained cDNA was analyzed by Real-
Time PCR using the IQ5 thermocycler and the SYBR green chemistry (Bio-Rad). 
The primers were designed and analyzed with Primer3 [100]. Primers efficiency 
was tested by performing standard curves and the efficiency of all primers was 
between 90% and 110%. The housekeeping gene TXN1 was used as an internal 
control for cDNA normalization. For quantification, expression levels were 
calculated by using the 2-ΔΔCt method. Real-Time PCR primer sequences were as 
follows: 
 
GAPDH:  
Fw 5’-CACCATCTTCCAGGAGCGAG-3’  
Rv 5’-CCTTCTCCATGGTGGTGAAGAC-3’ 
 
TXN1:  
Fw 5’-GGCTTCAAGCTTTTCCTTGTT-3’  
Rv 5’-TCCAATGTGGTGTTCCTTGA-3’ 
 
MICU1 all isoforms: 
Fw 5’-AAGGCAGCATCTTCTACAGCC-3’ 
Rv 5’-CCTGCTCAAACTCCTCCATGT-3’ 
 
MICU1 splice variant specific (NM_144822.3): 
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Fw 5’-GCGCTTTGATGGAAAGAAAATTGC-3’ 
Rv 5’-TGTCTACCTCTCCGTCTCCA-3’ 
 
MICU1.1 splice variant specific (NM_001291443.1): 
Fw 5’-CTTTGATGGAAAGGAGTTCTGGC-3’ 
Rv 5’-CCTCCATGTCTACCTCTCCGT-3’ 
 
MCU: 
Fw 5’-AAAGGAGCCAAAAAGTCACG-3’ 
Rv 5’-AACGGCGTGAGTTACAAACA-3’ 
 
MICU2: 
Fw 5’-TGGAGCACGACGGAGAGTAT-3’ 
Rv 5’-GCCAGCTTCTTGACCAGTGT-3’ 
 
The same samples of cDNA were used for standard PCR. Primers that span 
the extra-exon were designed with Primer3 and the PCR reaction was performed 
with 2x PCR master mix (Thermo Fisher Scientific). Electrophoresis separation of 
the PCR products was performed using acrylamide precast gels 20% in TBE buffer 
(Thermo Fisher Scientific) and DNA bands were detected thanks to GelRed nucleic 
acid gel stain (Biotium) after UV exposure. PCR primer sequences were as follows: 
 
Fw: 5’-GAACACTTGGGCCTGGATCA-3’ 
Rv: 5’-GAAGGAGATGAGCCCACACT-3’ 
 
Product size 152 bp for MICU1.1 and 140 bp for MICU1. 
Cell culture and transfection  
HeLa cells and C2C12 cells (ATCC) were cultured in DMEM (Thermo 
Fisher Scientific), supplemented with 10% FBS (Thermo Fisher Scientific), 
containing penicillin (100 U/ml) and streptomycin (100 μg/ml). Fully confluent 
C2C12 cells were differentiated in myotubes for 7 days using DMEM supplemented 
with 2% HS (Life Technologies) 
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Cells were transfected with a standard Ca2+-phosphate procedure. Briefly, 
the solution containing the desired amount of DNA and 250 mM CaCl2 was added 
quickly to an equal volume of HEPES Buffered Solution (HBS, 280 mM NaCl, 
50 mM Hepes, 1.5 mM Na2HPO4, pH 7.12). The solution was then added directly 
to the cell monolayer. 8-16 hours after addition of the transfection mix, cells were 
washed with PBS until the excess of precipitate is completely removed. 
Experiments were carried out 24-36 hours after transfection. Mock vectors (i.e., 
pcDNA3.1 or pEGFP-N1) were used as controls in all overexpression experiments. 
In parallel, a non-targeting siRNA (i.e., siRNA-scrambled) was used as a control in 
all silencing experiments. 
siRNA and constructs 
Mouse MICU1.1 was amplified from mouse skeletal muscle cDNA by For 
the cloning of MICU1.1-HA in pcDNA3.1: 
 
fw: 5’-CGGATCCGCCACCATGTTTCGTCTTAACACCCT-3’ 
rv: 5’-GCTCGAGTCACAGGGAAGCGTAGTCAGGCACATCGTAGGGGTATTTGG 
GCAGAGCAAAGTCCC-3’ 
 
The PCR fragment was cloned into BamHI and XhoI sites in pcDNA3.1 
(Thermo Fisher Scientific). 
 
To silence MICU1 specific leading siRNA sequences were designed: 
 
siRNA-MICU1#1: 5’-UCUGAAGGGAAAGCUGACAAU-3’ 
 
All the siRNAs and the non-targeting siRNA (siRNA-scrambled, MISSION 
siRNA Universal Negative Control #1, cat no. SIC001) were purchased from 
Sigma-Aldrich. pcDNA3.1-MCU-Flag, pcDNA3.1-MICU1-HA, pcDNA3.1-
MICU2-Flag, pcDNA3.1-MICU1EFmut-HA, pcDNA3.1-MICU2EFmut-Flag, 
pcDNA3.1-4mtGCaMP6f were previously described [47,52]. 
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Mutagenesis 
To create the mutant MICU1.1D233A,E244K,D423A,E434K, pcDNA3.1-MICU1.1-
HA was mutagenized using the following primers: 
 
5’-
TGAAATTGCTTTCAAGATGTTTGCCTTGAATGGAGACGGAGAGGTAGACATGGAGAA
GTTTGAGCAGGTTCAGAGC-3’ 
5’-
GTGGTGTTCGCGCTCTTTGCCTGTGATGGCAATGGGGAGCTGAGCAACAAGAAGTTC
GTTTCCATCATGAAGC-3’ 
 
To create the mutant MICU1.1E182A, pcDNA3.1-MICU1.1-HA was 
mutagenized using the following primers: 
 
5’-TAAAGCGCTTTGATGGAAAGGCTTTCTGGCAGAAAATTGCCCAG-3’ 
 
To create the mutant MICU1.1F183A, pcDNA3.1-MICU1.1-HA was 
mutagenized using the following primers: 
 
5’-AGCGCTTTGATGGAAAGGAGGCTTGGCAGAAAATTGCCCAGGA-3’ 
 
To create the mutant MICU1.1W184A, pcDNA3.1-MICU1.1-HA was 
mutagenized using the following primers: 
 
5’-CGCTTTGATGGAAAGGAGTTCGCGCAGAAAATTGCCCAGGAAC-3’ 
 
To create the mutant MICU1.1Q185A, pcDNA3.1-MICU1.1-HA was 
mutagenized using the following primers: 
 
5’ TTTGATGGAAAGGAGTTCTGGGCGAAAATTGCCCAGGAACGAG 3’ 
 
To create the mutant MICU1.1∆E182, pcDNA3.1-MICU1.1-HA was 
mutagenized using the following primers: 
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5’-AATAAAGCGCTTTGATGGAAAGTTCTGGCAGAAAATTGCCCAG-3’ 
 
To create the mutant MICU1.1∆F183, pcDNA3.1-MICU1.1-HA was 
mutagenized using the following primers: 
 
5’-AGCGCTTTGATGGAAAGGAGTGGCAGAAAATTGCCCAGGA-3’ 
 
To create the mutant MICU1.1∆W184, pcDNA3.1-MICU1.1-HA was 
mutagenized using the following primers: 
 
5’-CGCTTTGATGGAAAGGAGTTCCAGAAAATTGCCCAGGAACG-3’ 
 
To create the mutant MICU1.1∆Q184, pcDNA3.1-MICU1.1-HA was 
mutagenized using the following primers: 
 
5’-TTTGATGGAAAGGAGTTCTGGAAAATTGCCCAGGAACGAGAA-3’ 
 
To create the mutant MICU1.1E182A,F183A,W184A,Q185A, pcDNA3.1-MICU1.1-
HA was mutagenized using the following primers: 
 
5’-TAAAGCGCTTTGATGGAAAGGCCGCCGCCGCCAAAATTGCCCAGGAACGAGAA-3ì 
 
Mutagenesis was performed as previously described [101,102]. 
Western blotting and Antibodies 
To monitor endogenous and overexpressed proteins, cells were lysated in 
RIPA-buffer (150 mM NaCl, 50 mM Tris, 1 mM EGTA, 1% Triton X-100, 0.1% 
SDS) and after 30’ of incubation on ice, 40 μg of total proteins were loaded, 
according to BCA quantification (Thermo Fisher Scientific). Proteins were 
separated by SDS-PAGE electrophoresis, in commercial 4-12% acrylamide gels 
(Thermo Fisher Scientific) and transferred on nitrocellulose membranes (Thermo 
Fisher Scientific) by wet electrophoretic transfer. Blots were blocked 1 hour at RT 
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with 5% non-fat dry milk (BioRad) in TBS-tween (0.5M Tris, 1.5M NaCl, 0.01% 
Tween) solution and incubated at 4°C with primary antibodies. Secondary 
antibodies were incubated 1 hour at RT. Washes after antibody incubations were 
done on an orbital shaker, three times for 10 minutes each, with TBS-tween. We 
used the following antibodies: α-Flag and α-HA (1:1000, Cell Signaling 
Technologies), α-MICU1 (1:1000, Sigma-Aldrich), α-MICU2 (1:1000, Abcam). 
Secondary, isotype-specific HRP-conjugated antibodies (1:5000) were purchased 
from BioRad. 
Co-immunoprecipitation 
For co-immunoprecipitation experiments, HeLa cells were transfected with 
a calcium-phosphate procedure. After 48 hours of expression cells were lysate in 
an appropriate volume of lysis buffer (150 mM NaCl, 0.5% DDM, 50 mM Tris-
HCl pH 7.4, 1 mM EGTA-Tris pH 7.4 and Complete EDTA-free protease inhibitor 
mixture (Roche Applied Science)). 1 mg of proteins from the different conditions 
was incubated with 20 µL of monoclonal α-Flag-Agarose antibody (Sigma-Aldrich) 
overnight in rotation. The day after, agarose beads were washed 3 times with lysis 
buffer and the immune-complexes were broken by heating at 95°C for 5 minutes in 
SDS-sample buffer (Thermo Fischer Scientific). The co-immunoprecipitated 
proteins were separated by SDS-PAGE gel electrophoresis, transferred to 
nitrocellulose membrane (Thermo Fisher Scientific) and stained with Ponceau S 
solution.  
Mitochondrial purification from mouse tissues 
Purification of mitochondria was performed from mice skeletal muscle and 
liver. Adult male (3-4 months old) CD1 mice were used for all the experiments. 
The tissues of interest were rapidly collected from mice sacrificed by cervical 
dislocation and conserves in ice-cold PBS. Tissues were washed twice with ice-
cold PBS in order to remove the blood. The tissues were minced into small pieces 
using scissors in a small volume of homogenization buffer (HB, 250 mM Sucrose, 
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20 mM HEPES, 10 mM KCl and 1 mM EGTA). The pieces were homogenized 
using a glass potter and the homogenates were collected in a 50 mL tube. The 
samples were centrifuged for 10 minutes at 1000xg in a 4°C refrigerated centrifuge. 
The supernatants containing mitochondria were collected and centrifuged at 
10000xg for 20 minutes to precipitate the mitochondria enriched fraction. The 
pellets were washed with ice-cold HB and pelleted at 10000xg for 3 times. 
Mitochondrial protein extraction was performed with lysis buffer provided in the 
NativePAGE Sample Prep Kit (Thermo Fisher Scientific) with 1% DDM.  
BlueNative-Polyacrylamide gel electrophoresis (BN-
PAGE) 
BlueNative-gels were provided by Thermo Scientific and BN-PAGE was 
performed following the manufacturing protocol. In BN-PAGE, the Coomassie G-
250 was used to confer a net negative charge to the proteins, while maintaining the 
proteins in their native state without any protein denaturation. The G-250 is present 
in the cathode buffer to provide a continuous flow of G-250 into the gel, and is 
added to samples containing non-ionic detergent prior to loading the samples onto 
the gel. The binding of G-250 to proteins offers several advantages resulting in 
high-resolution native electrophoresis [103]. First, the proteins with basic 
isoelectric points (pI) normally have a net positive charge that are converted to 
proteins with a net negative charge, allowing the proteins to migrate in one direction 
towards the anode. Second, membrane proteins and proteins with significant 
surface-exposed hydrophobic area are less prone to aggregation as G-250 binds 
non-specifically to hydrophobic sites converting them to negatively charged sites. 
The mitochondria were lysed using the NativePAGE sample buffer (Thermo Fisher 
Scientific) supplemented with 0.5% DDM (Sigma Aldrich). Crude extracts were 
centrifuged at 15000xg for 10 minutes to remove debris, and proteins in the 
supernatant were quantified using the BCA Protein Assay Kit (Thermo Fisher 
Scientific). 20 μg of proteins were dissolved in 1x NativePAGE sample buffer 
(Thermo Fisher Scientific) and the samples were loaded in a NativePAGE Novex 
4–16% Bis-Tris Gels, that is able to resolve proteins in the molecular weight range 
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of 15-1,000 kDa. We used the NativeMark Unstained Protein Standard designed 
for molecular weight estimation of proteins, that was stained with Colloidal Blue 
Staining Kit (Thermo Fisher Scientific).  
Baculovirus/insect cells system and protein affinity 
purification 
Mus musculus MICU1, MICU1.1 and MICU2 coding sequences were 
cloned in the pFH vector suitable for expression in insect cell. MICU1 and 
MICU1.1. were cloned in frame with a 6xhistidine-tag sequence at the N-terminus. 
The baculovirus production and insect cells infection were performed as previously 
described [104]. 
The insect cells were collected by centrifugation at 6,000xg for 10 minutes 
at 4 °C. The cell pellet was resuspended in lysis buffer (50mM Tris HCl pH 8, 
200mM NaCl, 10% glycerol, 10mM imidazole, 1 mM DTT and 1 mM PMSF) and 
lysed in a French press (at 1.35 kbar; One Shot Constant System Cell Disrupter, 
from Constant Systems Ltd). A clarified crude extract was then obtained by 
centrifugation (20.000xg, 40 minutes, 4°C) and incubated 2 hours at 4 °C under 
mild shaking with 1 ml of nickel affinity gel (HIS-Select nickel affinity gel, Sigma-
Aldrich). At the end of this incubation, the mix was transferred into a 
chromatography column. The column was then washed with 5 volumes of lysis 
buffer, and after that the tagged proteins were eluted with 5 volumes of lysis buffer 
containing 300 mM imidazole. The elution fractions were pooled together, analysed 
by 12% Bis-Tris gel (NuPage, Thermo Fisher Scientific). For immunoblotting 
analysis, the gel was blotted on a nitrocellulose membrane that was probed with a 
monoclonal -6xHis tag (Cell Signaling) or -MICU2 (AbCam) antibody. To 
isolate the oligomeric state corresponding to the heterodimer MICU1-MICU2 and 
MICU1.1-MICU2, the affinity purified fractions were subjected to gel filtration 
chromatography. Gel filtration was performed with a Superdex 200GL 10/30 (GE 
Healthcare), equilibrated in 25 mM Tris-HCl pH 7,4, 150mM NaCl. The run was 
performed by injecting 500 l of the sample at a flow rate of 0.5 ml/min.  
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For bilayer experiments 2 mM EGTA is added to the samples to remove the 
residual Ca2+. The buffer is then replaced with 25 mM Tris-HCl pH 7,4, 150mM 
NaCl using PD10 column (GE Healthcare). 
Heterologous proteins expression  
Mus musculus MCU cDNA sequence was cloned in pIVEX1.4WG, suitable 
for in vitro expression. In vitro expression of pIVEX1.4WG:MCU was performed 
by using Wheat Germ CECF Kit (Roche), as previously reported [50]. After 
expression, the MCU was incorporated into proteoliposomes for bilayer 
experiments as previously described [47,50,52]. 
Mus musculus MICU1 and MICU1.1 cDNAs were cloned into a pACYC 
Duet vector (Novagen), suitable for heterologous expression in Escherichia coli, in 
frame with a StrepII tag coding sequence at the N-terminus. The sequences were 
optimized for prokaryotic expression and the first 96 amino acids were deleted to 
avoid aggregation, as previously observed [82]. E. coli BL21(DE3) cells were 
transformed with the recombinant plasmids and positive clones selected by 
antibiotic resistance. Transformed cells were grown overnight in selective LB 
medium and then subcultured the following day in fresh medium. The expression 
of the proteins was induced by adding 0.5 mM isopropyl-thiogalactopyranoside and 
incubating the cells at 22°C overnight. For protein purification, cells were harvested 
by centrifugation, resuspended in lysis buffer (25 mM Tris-HCl, pH 7.4, 200 mM  
NaCl, and 1 mM PMSF) and lysed by French press (at 1.35 kbar; One Shot Constant 
System Cell Disrupter, from Constant Systems Ltd). The supernatant fractions were 
isolated from the cells debris by centrifugation (20.000xg, 30 minutes, 4°C). Both 
proteins were purified to homogeneity by combining an affinity chromatography 
(StrepTactin-Sepharose suspension, IBA) and a gel filtration chromatography. Gel 
filtration was performed with a Superdex 200HR 10/30 (GE healthcare). For bilayer 
experiments 2 mM EGTA was added to the samples to remove the residual Ca2+. 
The buffer is then replaced with 25 mM Tris-HCl pH 7,4, 150mM NaCl using PD10 
column (GE Healthcare). 
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Electrophysiological experiments 
A Warner Instruments electrophysiological planar bilayer apparatus was 
used. Bilayers were prepared using purified soybean asolectin dissolved in decane 
(Sigma-Aldrich) containing 1% chloroform (Sigma-Aldrich) across a 250 µM hole 
in a polystyrene cuvette (Warner Instruments). Asolectin was purified by 
precipitation with cold acetone from a chloroform solution. The lipid membrane 
divided the trans and the cis compartments.  
When a bilayer membrane was formed, currents across the membrane 
elicited by different voltage pulses were measured and the membrane resistance 
could be determined. A bilayer membrane was considered to be satisfactory for 
further experiments if it exhibited an approximately 150–200 pF capacity. The 
volumes of the cis and trans compartments were 3 ml, that were stirred with a small 
magnetic bar upon need (e.g. after addition of proteins). Both sides were connected 
to the electrodes via salt bridges (1 M KCl) in series with Ag/AgCl electrodes. All 
voltages reported are those of the cis chamber, zero being assigned by convention 
to the trans (grounded) side. Currents are considered as positive when carried by 
cations flowing from the cis to the trans compartment.  
The standard experimental medium was 100 mM Na-gluconate, 10 mM 
HEPES and 5 mM EDTA (pH 7.4). The Ca2+-containing solution was the same but 
we added CaCl2 resulting in 1 μM free Ca2+ as calculated on WebMaxC version 2.2 
(http://www.stanford.edu/~cpatton/maxc.html).  
20 control experiments with empty membrane or with regulators alone (no 
MCU in the experiments) showed no activity in any of the above solutions. All 
measurements were carried out at room temperature. 
Data were acquired using a Bilayer Clamp amplifier (Warner Instruments, 
USA) at 100 s/point, filtered at 300 Hz and analysed offline using the pClamp 
program set (Axon Instruments, Union City, CA, USA). Histograms were fitted 
using Origin6.0 program set. Leak was not subtracted.  
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Aequorin Ca2+ measurements  
Aequorin is a 22 KDa photoprotein isolated from jellyfish Aequorea 
victoria that emits blue light in the presence of Ca2+. In its active form, the 
photoprotein includes an apo-protein and a covalently bound prosthetic group, 
coelenterazine. The apo-protein contains four helix-loop-helix EF-hand domains, 
three of which are Ca2+-binding domains [105]. When Ca2+ ions bind to the high 
affinity EF-hand sites, coelenterazine is oxidized to coelenteramide, with a 
concomitant release of CO2 and emission of light. Reconstitution of an active 
aequorin, expressed after cells transfection, can be obtained also in living cells by 
simple addition of coelenterazine into the medium. The advantage of genetically 
encoded probes is the possibility to target the probe to specific subcellular regions 
by fusing specific targeting sequences [106–108]. The possibility of using aequorin 
as Ca2+ indicator is based on the existence of a well characterized relationship 
between the rate of photon emission and the [Ca2+] [109].  
The aequorin detection system is derived from Cobbold and Lee description 
[110] and is based on the use of a low noise photomultiplier placed in close 
proximity (2-3 mm) of aequorin expressing cells. The cell chamber is adapted to fit 
13 mm diameter coverslips. Cells are continuously perfused via peristaltic pump 
with medium thermosted at 37°C. The photomultiplier (Hamamatsu H7301) is kept 
in a dark box. The output of the amplifier-discriminator is captured by C8855-01 
photon counting board in an IBM compatible microcomputer and stored for further 
analysis.  
Experimental procedure 
Cells transfection. HeLa cells were seeded on 13 millimetres (mm) 
coverslip at 60% confluency in a 24 wells plate. The day after cells were transfected 
with calcium phosphate procedure with the appropriate mix of DNA (in an 
aequorin/total DNA ratio of 1:4). The plasmids encoding aequorin based Ca2+ 
probes are cytosolic aequorin (cytAEQ) [111] and mutant aequorin targeted to 
mitochondria (mitAEQmut) [112,113]. The cytAEQ displays a range of [Ca2+] 
sensibility between 10-4 and 10-7 M under physiological conditions of pH, 
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temperature and ionic strength. The mtAEQmut construct includes the targeting 
pre-sequence of subunit VIII of human cytochrome c oxidase fused to the aequorin 
cDNA. To expand the range of Ca2+ sensitivity that can be monitored the 
photoprotein was also mutated (Asp119>Ala). This point mutation affects 
specifically the second EF-hand motive of wild type aequorin. The affinity for Ca2+ 
of this mutated aequorin (mtAEQmut) is about 20 fold lower than that of the wild 
type [35]. 
Reconstitution. After 24 hours of transfection, 2 hours before the 
experiment, aequorin apoprotein was reconstituted by adding the prosthetic group, 
native coelenterazine (Molecular Probe). Cells were washed with Krebs–Ringer 
modified buffer (KRB: 135 mM NaCl, 5 mM glucose, 5 mM KCl, 1 mM CaCl2, 1 
mM MgSO4, 0.4 mM K2HPO4, 20 mM HEPES, pH=7.4) and then incubated with 
5 µM coelenterazine for 2 hours in KRB saline. 
Ca2+ measurements. After the reconstitution phase, cells were transferred to 
the perfusion chamber. All aequorin measurements were carried out in modified 
KRB saline solution. Agonists and other drugs were added to the same solution. 
The agonist stimuli used for maximal stimulation was 100 μM histamine, which is 
an agonist of G proteins-coupled receptor H1, that is able to induce the generation 
of GAG and IP3, and thus the release of Ca2+ from the ER through IP3R. The 
experiments were terminated by lysing cells with 100 μM digitonin (Sigma-
Aldrich) in a hypotonic Ca2+-rich solution (10 mM CaCl2 in H2O), thus discharging 
the unbound aequorin pool.  
Alternatively, aequorin measurements were carried out on a PerkinElmer 
EnVision plate reader equipped with a two-injector unit. Cells were transfected as 
described above in 24-well plates and then re-plated on 96-well plates (1:5 dilution) 
the day before the experiment. After reconstitution with 5 μM coelenterazine, cells 
were placed in 70 μl of KRB and luminescence from each well was measured for 1 
min. During the experiment, histamine was first injected at the desired 
concentration to activate Ca2+ transients, and then a hypotonic, Ca2+-rich, digitonin-
containing solution was added to discharge the remaining aequorin pool. Output 
data were analysed and calibrated with a custom-made macro-enabled Excel 
workbook.  
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Mitochondrial Ca2+ uptake in permeabilized cells. HeLa cells were 
transfected with the mtAEQmut construct, using calcium phosphate procedure (see 
above). 24 hours after transfection, 2 hours before the experiment, the protein was 
reconstituted by adding the prosthetic group, native coelenterazine. After aequorin 
reconstitution, cells were perfused for 60 seconds with a buffer mimicking the 
cytosolic ionic composition (IB: 130 mM KCl, 10 mM NaCl, 2 mM K2HPO4, 5 
mM succinic acid, 5 mM malic acid, 1 mM MgCl, 20 mM HEPES, 1 mM pyruvate, 
at pH 7) supplemented with 100 μM EGTA (IB/EGTA). Cells were then perfused 
with IB/EGTA buffer with 50 µM digitonin for 60 second to permeabilize the 
plasma membrane. After that, cells were washed with IB/EGTA buffer for other 60 
second. Then cells were perfused with a known EGTA-buffered [Ca2+] solution, at 
the indicated concentration of free-Ca2+. Calculated [Ca2+]free was predicted with 
CHELATOR software [114] and confirmed fluorimetrically with the Fura2 free 
acid form. After mitochondrial Ca2+ uptake, the experiments were terminated by 
lysing cells with 100 μM digitonin (Sigma-Aldrich) in a hypotonic Ca2+-rich 
solution (10 mM CaCl2 in H2O), thus discharging the unbound aequorin pool. 
Mitochondrial Ca2+ uptake speed was calculated as the first derivative, by using the 
SLOPE Excel function smoothed for three time points. The higher value reached 
during Ca2+ addition represents the maximal Ca2+ uptake speed.  
Measurement of Mitochondrial Membrane Potential 
The measurement of mitochondrial membrane potential is based on the 
distribution of the mitochondrion-selective lipofilic cation tetramethyl-rhodamine 
methyl ester dye (TMRM, Thermo Fisher Scientific). This indicator is fluorescent 
and membrane permeable and its distribution into intracellular compartments is 
triggered by electrochemical gradients thanks to its positive charge. Hence, at low 
concentrations, its accumulation into mitochondria was shown to be driven by 
mitochondrial membrane potential (almost -180mV). In order to promote the 
correct distribution of the probe, cells were loaded with the dye-solution at very low 
concentration (20 nM). Changes in mitochondrial membrane potential cause a 
redistribution of the dye between mitochondria and cytoplasm. Cells were loaded 
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with TMRM stock solution (in modified KRB saline solution) for 20 min at 37°C. 
The probe was excited at 560 nm and the emission light was recorded in the 590-
650 nm range.  
Images were taken every 5 seconds with a fixed 200 ms exposure time. 
FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone, 10 μM), an 
uncoupler of oxidative phosphorylation, was added after 12 acquisitions to 
completely collapse the electrical gradient established by the respiratory chain 
(ΔΨ). Data are expressed as difference between the TMRM fluorescence before and 
after FCCP depolarization. TMRM imaging were performed on an inverted Zeiss 
Axiovert 200 equipped with a 40x 1.3N.A. objective. Images were collected with a 
back-illuminated EMCCD camera (Photometrics Cascade 512B) at 200-300 ms 
exposure time. Probe was excited by a 300W Xenon arc lamp (Sutter Lambda LS) 
with a 543/22 nm filter and collected through a 593/40 nm emission filter.  
Immunofluorescence 
HeLa cells were grown on 13 mm coverslips and transfected with MICU1-
HA or MICU1.1-HA constructs and/or mtRFP encoding plasmid. After 24/36 
hours, cells were washed with PBS, fixed in 4% formaldehyde for 10 minutes and 
quenched with 50 mM NH4Cl in PBS. Cells were permeabilized for 10 minutes 
with 0.1% Triton X-100 in PBS and blocked in PBS containing 2% BSA for 1 hour. 
Cells were then incubated with primary antibodies (α-HA, Cell Signaling 
Technologies) for 3 hours at room temperature and washed 3 times with PBS. 488 
AlexaFluor conjugated secondary antibodies (Thermo Fisher Scientific) were used 
and coverslips were mounted with ProLong Gold Antifade reagent (Thermo Fisher 
Scientific). Images were acquired on a Leica TCS-II SP5 STED CW system 
equipped with a 100×/1.4 N.A. Plan Apochromat objective. For all images, pinhole 
was set to 1 airy unit, pixel size was about 100 nm. 488 nm Ar-laser line was used 
to excite Alexa-488 and its signal collected in the 492-537 nm range, while RFP 
fluorescence was excited by the 543 nm HeNe laser and its emission was collected 
in the 555-700 nm range. For each image, PMT gain was slightly adjusted in order 
to maximize signal and avoid saturation. 
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Mitochondrial targeted GCaMP6f measurements 
HeLa cells were grown on 24 mm coverslips and transfected with 
4mtGCaMP6f-encoding plasmids together with the indicated constructs (ratio 
probe/other constructs 1:8). After 24 hours, coverslips were placed in 1ml of 
modified KRB (5.5 mM glucose, 1 mM CaCl2) and imaging was performed on a 
Zeiss Axiovert 200 microscope equipped with a 63×/1.4 N.A. Plan Apochromat 
objective. Excitation was performed with a DeltaRAM V high-speed 
monochromator (Photon Technology International) equipped with a 75 W xenon 
arc lamp. Images were captured with a high-sensitivity Evolve 512 Delta EMCCD 
(Photometrics). The system is controlled by MetaMorph 7.5 (Molecular Devices) 
and was assembled by Crisel Instruments. In order to test resting [Ca2+]mt with high 
sensitivity, a Ca2+ probe based on the last-generation GCaMP probe was generated 
[115] targeted to the mitochondrial matrix. The GCaMP6 family of is a collection 
of ultrasensitive, green fluorescent indicator proteins that enable reliable detection 
of fast Ca2+ transient (excitation [Ca2+]-dependent at 474 nm). HeLa cells were 
alternatively illuminated at 474 and 410 nm and fluorescence was collected through 
a 515/30 nm band-pass filter (Semrock). Exposure time was set to 200 ms at 474 
nm and to 400 ms at 410 nm, in order to account for the low quantum yield at the 
latter wavelength. At least ten fields were collected per coverslip, and each field 
was acquired for 10 s (1 frame/s). Analysis was performed with the Fiji distribution 
of ImageJ. Both images were corrected for the background frame by frame by 
subtracting the mean pixel values of a cell-free region of interest. Data are presented 
as the mean of the averaged ratio of all time points. 
 
Cut of the sciatic nerve of CD1 mice 
Four right hindlimbs for each time points of 3 months old CD1 mice were 
denervated cutting unilaterally the sciatic nerve. The animals were anesthetized by 
an intraperitoneal injection of ketamine (75 mg/Kg) and xylazine (20 mg/Kg). The 
sciatic nerve was unilaterally cut at the level of trochanter. About 0.5-1 cm of the 
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peripheral nerve stump was removed and the proximal stump was sutured into a 
superficial muscle to avoid reinnervation and obtain a permanent denervation of the 
lower hindlimb. 3 and 7 days after the injury, the animals were sacrificed by cervical 
dislocation. At the indicated time point the tibialis anterior (TA) and extensor 
digitorum longus (EDL) muscles were dissected out from the denervated hindlimbs 
and frozen in liquid nitrogen. The muscles were utilized for gene expression studies 
(see above for RNA extraction and Real-Time PCR procedures). The contralateral, 
innervated muscles were used as control. The experiments were approved by 
institutional review boards. 
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